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ABSTRACT 
 
 
 
 
 
Crude plant extracts and natural products deriving from them have been used since ancient 
in folk medicine for treating a broad range of human diseases and, according to the World 
Health Organization (WHO) reports, plant-derived traditional medicines are still playing an 
important role in the health care systems of developed countries. However, although the last 
decade has witnessed a marked growth in the market of plant-based natural products, their 
high complexity in terms of composition makes a challenging task the guarantee of quality, 
efficacy and safety requirements. In such scenario, the recently approved European regulation 
EU 2017/745 has created a breaking point in the regulation of medical devices forcing the 
manufactures to investigate the overall qualitative composition of devices made of substances 
and quantitative information for the main constituents or for the components responsible for 
the desired effect. In view of this stricter standardization of plant-based medical devices, an 
intense research towards advanced technologies and robust analytical protocols is required 
both for evaluating the composition in metabolites and for reaching the required quality 
standards.  
Based on these considerations, in this Philosophiae Doctor Thesis, Grintuss® syrup was 
selected as a case study of formulated natural complex products for quali-quantitative 
metabolomics investigations. In particular, in the first part of this dissertation, an untargeted 
metabolomic approach for monitoring the batch-quality of Grintuss® adult syrup by 
electrospray ionization mass spectrometry flow injection analysis (FIA-ESI-MS) was successfully 
developed (Chart I). The proposed workflow has involved the preliminary sample preparation 
followed by its analysis by FIA-ESI-MS. Thus, after having assessed the validity of the model by 
using multivariate statistical process control (MSPC), the quality verification of new batches 
under investigation was achieved by comparing their profile with the fingerprinting profile of 
batches prepared according to the optimized manufacturing process, and validated by 
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traditional continuous quality verification throughout the production chain, and the profile 
obtained from batches deriving from pre-established production errors. 
The second task of this doctoral work was aimed at profiling the metabolites contained in 
Grintuss® pediatric syrup by applying a targeted metabolomic LC-MS-based approach (Chart I). 
In pursuing this aim, an in-house database of high-purity standard reference compounds was 
built by collecting compounds belonging to different chemical classes. Thus, after the 
acquisition of MS and MS/MS spectra of standard compounds of interest, the matching 
between the detected metabolites from samples of Grintuss® syrup and standard reference 
compounds from the database was assessed by following the All Ions MS/MS targeted 
screening workflow from Agilent Technologies. Finally, the quantitative analysis of the 
recognized metabolites was performed and the results thus achieved have been combined with 
information deriving from the analysis of additional compounds as mono-, di- and 
polysaccharides, fats and minerals allowing to reach the knowledge of >99.9% of the overall 
composition of Grintuss® pediatric syrup. 
 
 
 
Chart I  ̶  Targeted and untargeted mass spectrometry-based approaches for the metabolomics 
investigation of Grintuss® syrup. 
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1 Introduction 
 
 
 
 
 
1.1 Plants as an endless source of biologically active metabolites 
Nature has been a priceless source of inspiration since ancient.1 Indeed, if on one side 
natural products (NPs) from plants and animals have been a rich source of biologically-active 
compounds, still continuing to enthral the scientific community for the impressive complexity 
and diversity of chemotypes, on the other side chemists have always tried to mime Mother 
Nature reproducing artificially NPs themselves.2 Despite the reduced investments for NP-based 
drug discovery especially in the big Pharma during the last two decades,3 nowadays the deeper 
understanding of the biological pathways, the unremitting advances in the "omics" disciplines 
and the availability of novel investigating hyphenated techniques allow the rapid identification 
and characterization of new biologically-active secondary metabolites as an endless source of 
new medicines. Plants, in particular, represent the main source of biologically-active NPs and 
secondary metabolites (Box 1).4  
 
Box 1. Main classes of pharmacologically-active secondary plant metabolites. 
Plant secondary metabolites are defined as molecules that do not possess recognized roles in the 
maintenance of fundamental life processes in the plants but are mainly involved in modulating the 
interaction of the plant with its environment. The production of these compounds is often low and 
strongly depends on the physiological and developmental stage of the plant. Secondary metabolites are 
characterized by enormous chemical diversity and every plant has its own characteristic set of secondary 
metabolites.
5
 Based on their biosynthetic origins, plant secondary metabolites can be structurally divided 
into three major groups which include terpenoids, alkaloids and phenolics, while glycosides, tannins and 
saponins are part of them according to their specific structure.
6
 
Terpenoids 
Terpenoids are polymeric isoprene derivatives synthesized from acetate via the mevalonate pathway. The 
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high volatility of some terpenoids provides, for sessile plants, a tool for communicating with other 
organisms such as neighboring plants, pollinators and foes of herbivores, via air-bone info-chemicals. 
Recent findings demonstrate that certain nitrogenous terpenes possess potent anti-hypertensive activity, 
while the antimicrobial and insecticidal properties of other terpenoids have led to their utilization as 
pesticides and fungicides in agriculture.
6
  
    
Representative examples of biologically-active terpenoids and steroids 
Alkaloids  
Alkaloids represent a group of secondary metabolites characterized by the presence of basic nitrogen 
atoms, although some related compounds with neutral and weakly acid properties are also included in 
this group. In addition to carbon, hydrogen and nitrogen, this group may also contain oxygen, sulfur and 
rarely other elements such as chlorine, bromine and phosphorus. Most of them are toxic to other 
organisms and can be extracted by acid-base. They are biosynthesized from amino acids such as tyrosine 
and are endowed with diverse pharmacological effects. Compared with most other classes of secondary 
metabolites, alkaloids are characterized by a great structural diversity and there is no uniform 
classification of them.
6 
 
              
Representative examples of biologically-active alkaloids 
Phenols 
Phenolic compounds are one of the largest group of secondary plants constituents present in fruits, 
vegetables, teas, cocoa and other plants that possess certain health benefits. They are endowed with 
antioxidant, anti-inflammatory, anti-carcinogenic and other biological properties, and may protect from 
oxidative stress and some diseases. Phenolic compounds are distributed in almost all plants and are 
diverse in structure, while sharing the presence of aromatic rings as the common feature. Most of the 
phenolic compounds are polymerized into larger molecules such as proanthocyanidins and lignans. 
Furthermore, phenolic acids may occur in food plants as esters or glycosides conjugated with other 
natural compounds such as flavonoids, alcohols, hydroxyfatty acids, sterols, and glycosides. Phenols can 
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be classified in sub-families based on the number of hydroxyl groups (1-, 2- and polyatomic phenols), the 
chemical composition (mono-, di-, oligo- and polyphenols) and the number of aromatic rings present in 
the skeleton (one aromatic ring, two aromatic rings, quinones and polymers). Among them, polyphenolic 
compounds are the most common secondary metabolites in plants, including more than 8000 different 
compounds that share similar chemical structures but with some distinctive differences. Based on these 
differences, polyphenols can be classified into flavonoids, tannins and glycosides. The sub-family of 
flavonoids includes anthocyanins, flavones and flavonols, a series of water-soluble pigments found in the 
vacuoles of plant cells. They are widely distributed in plants, fulfilling many functions such as flower 
coloration, producing yellow, red or blue pigmentation in petals designed to attract pollinator animals. 
They have become very popular because of their health benefits which include anti-allergic, anti-cancer, 
antioxidant, anti-inflammatory and anti-viral activity. Tannins are water soluble phenolic compounds (with 
exception of some high molecular weight structures) generally in form of oligomers and polymers that are 
able to form complexes and precipitates with proteins, starch, cellulose and minerals. Tannins are 
synthesized via shikimic acid pathway, also known as the phenylpropanoid pathway. Tannins are used as 
astringent against diarrhea, diuretic against stomach and duodenal tumors, and anti-inflammatory agents. 
Glycosides may be phenol, alcohol or sulfur compounds. They are characterized by a sugar portion or 
moiety attached to one or non-sugar portions. Many plants store chemicals in the form of inactive 
glycosides, which can be activated by enzymatic hydrolysis. Saponins are largely distributed in plants and 
are characterized by the presence of a glycoside whose aglycone is related to a triterpenoid or steroidal 
sub-structure. They are endowed with particular biological (antimicrobial, antioxidant, hemolytic) and 
physicochemical (emulsification, solubilization, foaming) properties exploited in food, cosmetics and 
pharmaceutical industries. 
              
Representative examples of biologically-active phenols 
 
Historically, the earliest record concerning the use of plants for medical purposes dates back 
to 2600 B.C. on clay tablets (Mesopotamia). These include oils from Cedrus (cedar), Cupressus 
sempervirens (cypress), Glycyrrhiza glabra (licorice) and Commiphora (myrrh) species, and juice 
from Papaver somniferum (poppy), which are still used today to treat coughs, colds and 
inflammation.7 The Ebers Papyrus (2900 B.C.) represents the best known example of 
pharmaceutical record which documents the use as medicine of over 700 plant-based drugs 
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ranging from gargles and pills to infusions. The Chinese Materia Medica (1100 B.C., 52 
prescriptions)8 and the Indian Ayurvedic system (1000 B.C., more than 500 drugs)9 are others 
well documented records concerning the use of natural products. After that, the Greek 
physician Dioscorides (100 A.D.) recorded the collection, storage and use of medicinal herbs, 
while Galen, a practitioner and teacher of pharmacy and medicine in Rome, is known for his key 
contribute in the prescription and formulation of plant-based natural products used in therapy. 
During the Middle Ages, the Arabs expanded the Greco-Roman expertise by including new NPs 
deriving also from Chinese and Indian herbs. However, since the 18th century, medicinal plants 
were used without any rationalized mechanistic knowledge of their pharmacological activities. 
In this regard, Anton von Störck and William Withering, with their investigations towards 
poisonous herbs laid the basis for the rational use of medicinal plants.10  
Therefore, at the beginning of the 19th century, numerous bioactive components from 
medicinal plants have been identified, isolated and extensively studied, while apothecaries, the 
progenitors of the modern pharmaceutical companies, specialized itself in the purification and 
formulation of biologically-active NPs.11 Subsequently, several efforts were made in order to 
make available NPs at lower costs by chemical synthesis. After the "penicillin era", with the 
advancements in the field of chemistry in the mid-twentieth century, formulated single natural 
products superseded the crude plant extracts generally utilized by apothecaries at the 
beginning of 1900.12 In recent years, plants have been extensively investigated for their 
therapeutic potential and have been the forefront of Ayurvedic and folk medicine to treat 
several human diseases.1a Indeed, in 1985 the World Health Organization (WHO) estimated that 
approximately 65% of the world population relied on plant-derived traditional medicines for 
their primary health care, while plant products also play an important indirect role in the health 
care systems of developed countries.13 In this regard, however, we are still so far from 
exploring the whole chemical space of NPs since more than 90% of the world’s biodiversity, 
estimated at 2 million species of plants, animals, fungi and micro-organisms, has not been 
evaluated for any potential biological activity.1a,3c,14 Furthermore, restricting the field to the 
terrestrial flora, it is estimated that only 15% of the approximately 300,000-500,000 species 
have been phytochemically investigated, while only 6% have been systematically investigated 
on a pharmacologically standpoint.1b,15 The growing interest in NP-based drug discovery can be 
demonstrated by analyzing the PubMed publications trend in this area in the period 1982-2012 
(Figure 1).11 
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Figure 1  ̶  PubMed publication trend analysis in plant-derived natural product pharmacology, chemistry, 
and drug discovery in the period 1982-2012.11 
 
In another interesting study, Koehn and co-authors examined the worldwide patent trends 
between 1984 and 2003 in NP discovery (Figure 2).3a Interestingly, although the restricted 
industrial funding for NP drug discovery in the same period, the percentage of NPs-based 
patents has remained basically constant, with a slight increase in the patent activity through 
the 1980s, a slight decline from 1990 to 1999 and a novel increase between 2000 and 2003 
(Figure 2). 
 
 
Figure 2  ̶  Worldwide natural products-based patent between 1984 and 2003.3a 
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Cragg and Newman have extensively reviewed the state of the art of NP-derived therapeutic 
agents over the years.1b,14d,16 Of the 1073 small molecules new chemical entities (NCEs) entered 
into the market over the period 1981-2010, 34% are NP inspired or derived (6% unmodified NPs 
and 28% modified NPs) (Figure 3). However, of the 66% of NCEs that are considered “formally 
synthetic”, only 36% of them can be classified as truly synthetic since 16% correspond to 
synthetic molecules containing pharmacophores derived directly from NPs and 14% are actually 
modeled on a NP inhibitor of the molecular target of interest or mimic the endogenous 
substrate of the active site (Figure 3).1b Considering two of the main disease categories, 69% of 
anti-infectives and 75% of anti-tumoral agents are naturally derived or inspired.  
 
 
Figure 3 ̶ Sources for the new chemical entities launched on the marked over the period 01/1981-
12/2010 (n= 1073). N: unmodified natural products; NB: botanical natural products; ND: modified 
natural products; S: synthetic compounds with no natural product conception; S*, S*/NM: synthetic 
compounds with a natural product pharmacophore with NM indicating competitive inhibition; S/NM: 
synthetic compounds showing competitive inhibition of the natural product substrate.1b 
 
During the last century, the relative number of NP-based approved drugs varied from 33% in 
the 1950s to more than 50% in 1930s and 1970s, while in 1970s the relative and then absolute 
number of NP-based NCEs approved began to decline. Finally, in the last three decades (1984-
2014), there has been a revitalized interest in NP-based drug discovery as witnessed by the 
average of NP-based NCEs approved per year in therapy (7.7, with a maximum of 10.3 in 1990) 
(Table 1) and investigated in clinical trials in 2014 (Table 2).11,17  
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Table 1  ̶  NP-based drugs approved for therapeutic use in the last thirty years (1984-2014).11 
 
Structure 
Generic name 
(Trade name) 
Plant species 
Indication  
(mechanism of action) 
 
Artemisinin (Artemisin) Artemisia annua L. Malaria treatment  
 
Arglabin (Arglabin) 
Artemisia globella Kar. et 
Kir., Artemisia obtusiloba 
var. glabra Ledeb. 
Cancer chemotherapy  
 
Capsaicin (Qutenza) 
Capsicum annum L., or  
C. minimum Mill. 
Postherpetic neuralgia  
 
Colchicine (Colcrys) Colchicum spp. Gout  
 
Dronabinol+Cannabidiol 
(Sativex) 
Cannabis sativa L. Chronic neuropathic pain  
 
 
Galanthamine 
(Razadyne) 
Galanthus caucasicus 
(Baker) Grossh. 
Dementhia associated 
with Alzheimer’s disease  
 
Ingenol mebutate 
(Picato) 
Euphorbia peplus L. Actinic keratosis 
 
Masoprocol (Actinex) 
Larrea tridentata (Sessè 
& Moc. ex DC.) Coville  
Cancer chemotherapy 
 
Omacetaxine 
mepesuccinate (Synribo) 
Cephalotaxus 
harringtonia (Knight ex 
Forbes) K. Koch 
Oncology 
 
Paclitaxel (Taxol) Taxus brevifolia Nutt. Cancer chemotherapy 
 
Solamargine (Curaderm) Solanum spp. Cancer chemotherapy 
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Table 2  ̶  NP-new chemical entities currently in clinical trials in 2014.11 
 
 
As evident from these data, several blockbuster drugs are based on naturally derived or 
inspired products as the anti-tumoral agents taxol (Paclitaxel®), isolated from Taxus brevifolia, 
trabectedin (Yondelis®), isolated from the sea squirt, and mevastatin produced by Penicillium 
citrinum that led to the synthetic statin Rosuvastatin (Crestor®), one of the top 15 worldwide 
best-selling drugs in 2015,18 just to name a few. Based on these data, it would be unbelievable 
to think about the patient life without statins, angiotensin antagonists and angiotensin-
converting-enzyme inhibitors, most of the anticancer and antibacterial drugs, 
immunosuppressive agents and other naturally derived or inspired top selling drugs. However, 
beyond single-molecule NP-based drugs, NP extracts, also defined as multicomponent botanical 
therapeutics (MCBTs)3b or phyto-pharmaceuticals,3c also play a key role in modern therapy as 
Structure Generic name Plant species Indications 
 
-Lapachone 
Haplophragma 
adenophyllum (Wall. ex 
G. Don) Dop  
Solid tumors 
 
Curcumin 
Curcuma longa L. 
(Turmeric) 
Cognitive impairment, 
cancer, schizophrenia, 
inflammation, depression, 
cardiovascular disease 
 
Epigallocatechin-3-O-
gallate 
Camellia sinensis (L.) 
Kuntze (Green tea) 
Epstein-Barr virus 
reactivation in remission 
patients, Alzheimer 
disease, cystic fibrosis, 
obesity 
 
Genistein Genista tinctoria L. 
Colon cancer, rectal 
cancer, adenocarcinoma, 
osteoporosis 
 
Gossypol Gossypium hirsutum L. 
B-cell chronic lymphocytic 
leukemia, refractory 
chronic lymphocytic 
leukemia 
 
Picropodophyllotoxin 
Podophyllum 
hexandrum Royle 
Glioblastoma, anaplastic 
astrocytoma 
 
Quercetin Allium cepa L. 
Chronic obstructive 
pulmonary disease, 
diabetes mellitus, heart 
disease 
 
Resveratrol Vitis vinifera L. 
Diabetes, lipid metabolism 
disorders, cardiovascular 
disease 
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dietary supplements, food additives, cosmetics, medical devices and medicines.19,20,21 In this 
regard, the drug discovery journey for phyto-pharmaceuticals generally starts with the 
knowledge concerning the use of medicinal plants in the traditional medicine and with the 
subsequent ethno-medicinal and ethno-botanical studies of traditional medicines that may lead 
to the identification and isolation of their bioactive components. After that, clinical trials on NP 
extracts are powerful tools for finding new targets by applying a target-based drug discovery 
approach known as reverse pharmacology (Figure 4).22  
 
 
Figure 4  ̶  Drug discovery journey for phyto-pharmaceuticals.22 
 
From a pharmacological point of view, due to the concomitant presence of several bioactive 
components, the clinical efficacy of a typical plant extract is not always explainable by 
considering the effect of the single active NP since synergistic effects are likely to occur.  
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Synergistic effects may include multiple aspects including multi-targets effect, mutual 
interaction between two components of the same extract able to improve the pharmacokinetic 
profile of one of the two components, enhanced efficacy of one component due to the 
inhibition of its metabolism by another component.23 Although synergistic effects are difficult 
to prove, the experimental demonstration of a given synergistic effect can be achieved by 
comparing the pharmacological effects of the mono-substances versus the combination of 
substances by analyzing isobole curves based on data from several dose combinations.23 These 
kind of studies allow to discriminate between simple additive effects, antagonistic interactions 
or real synergism with potentiated or additive effects.24 Poly-pharmacology, systems biology 
and synergistic effects may explain why whole plants extracts are often considered 
therapeutically superior over the single isolated constituents.25 
Herbal phyto-pharmaceuticals have reached 60 USD billion with an annual growth rates of 5-
15% due to their increased usage in therapy, especially in psychosomatic, metabolic and minor 
disorders.26 This remarkable sudden success is mainly related to the approval of several phyto-
pharmaceutical drugs worldwide in the last ten years. For example, in 2002 the European 
Medicines Agency (EMA) approved and granted as orphan drug the medicinal specialty known 
as NexoBrid®, a concentrate of proteolytic enzymes from the pineapple plant for the removal of 
damaged tissue caused by severe burn wounds.3c Moreover, FDA approved Veregen®, a 
mixture of Tea catechins for the treatment of genital diseases caused by human papilloma 
virus,20b and Fulyzaq®, an extract from the red sap of the Croton lechleri, for the treatment of 
HIV diarrhea.27 Sativex® is a well-known titrated extract containing an association between the 
psychoactive-9-tetrahydrocannabinol and the anti-inflammatory cannabidiol. Sativex® has 
been approved since 2005 in different countries as oro-mucosal spray for the treatment of 
spasticity due to multiple sclerosis and neuropathic breads.3c More recently, in 2012, the dry 
extract of Dioscorea nipponica was approved in Germany for the treatment of headache, 
muscle pain and cramps, representing the first traditional Chinese medicine approved in EU.3c  
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1.2 Legal requirements and regulatory guidelines for the quality control of herbal medicinal 
products and medical devices for human use in the European Union  
Although the last decade has witnessed a marked growth in the market of plant-based 
natural products, their high complexity in terms of composition still makes a challenging task 
the guarantee of quality, efficacy and safety requirements.28 Among different herbal products it 
is possible to distinguish: medicines or drugs, medical devices, food/dietary supplements, novel 
foods, functional foods and cosmetics (Table 3).29,30 
 
Table 3  ̶  Definitions of drug, medical device, food/dietary supplement, novel food, functional food and 
cosmetic.29,30 
Type of product Definition 
Medicine or drug 
(a) Any substance or combination of substances presented as having properties 
for treating or preventing disease in human beings;  
(b) Any substance or combination of substances which may be used in or 
administered to human beings either with a view to restoring, correcting or 
modifying physiological functions by exerting a pharmacological, immunological or 
metabolic action, or to making a medical diagnosis. 
 
Medical device 
Any instrument, apparatus, appliance, software, material or other article, 
whether used alone or in combination, including the software intended by its 
manufacturer to be used specifically for diagnostic and/or therapeutic purposes 
and necessary for its proper application, intended by the manufacturer to be used 
for human beings for the purpose of: diagnosis, prevention, monitoring, 
treatment, or alleviation of disease; diagnosis, monitoring, treatment, alleviation 
of or compensation for an injury or handicap; investigation, replacement or 
modification of the anatomy or of a physiological process; control of conception 
and which does not achieve its principal intended action in or on the human body 
by pharmacological, immunological, or metabolic means, but which may be 
assisted in its function by such means. 
 
Food/dietary supplement 
A product intended for ingestion that contains a "dietary ingredient" intended to 
add further nutritional value to (supplement) the diet. A "dietary ingredient" may 
be one, or any combination, of the following substances: a vitamin; a mineral; an 
herb or other botanical; an amino acid; a dietary substance for use by people to 
supplement the diet by increasing the total dietary intake; a concentrate, 
metabolite, constituent, or extract. 
 
Novel food 
Food that has not been consumed to a significant degree by humans in the EU 
prior to 1997, when the first Regulation on novel food came into force. 
'Novel Food' can be newly developed, innovative food or food produced using new 
technologies and production processes as well as food traditionally eaten outside 
of the EU. 
 
Functional food 
A food given an additional function (often one related to health-promotion or 
disease prevention) by adding new ingredients or more of existing ingredients. 
Cosmetic 
Intended to be applied to the human body for cleansing, beautifying, promoting 
attractiveness, or altering the appearance without affecting the body's structure or 
functions. 
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Recently, within the EU, appropriate regulatory actions have been undertaken to regulate 
and harmonize the legal status of these various groups of plant preparations throughout the 
different European countries.  
In case of herbal medicines, the herbal substance (i.e. the starting plant material) and/or the 
herbal preparation (i.e. the plant extract, tincture, exudates, fatty oil, essential oil) represents 
the active substance. Therefore, the quality of the herbal active substance must be assured in 
such a way that reliable and reproducible therapeutic success is guaranteed from batch to 
batch.29 In contrast to active pharmaceutical ingredients (APIs) derived from traditional 
chemical synthesis, starting materials from plants are subjected to a considerable variability 
involving not only the content of the active fractions but also the concomitant presence of 
additional components and contaminants of different origin. In this regard, genetic factors and 
growing conditions such as climate, soil quality and pests may affect the overall spectrum of 
constituents and therefore the quality of the plant material. Furthermore, harvesting and 
drying conditions, pre- and post-harvest treatments with pesticides and fumigants, as well as 
comminuting and storage conditions are further factors that may affect the quality of the 
herbal substance. The characterization of herbal extracts involves the detailed investigation of 
all the botanical and phytochemical aspects of the plant, macroscopic and microscopic assays 
and purity tests performed according to the requirements of the European Pharmacopoeia (EP). 
Besides the conventional purity tests, herbal substances have to meet additional requirements 
due to their origin including tests for heavy metals, residues of pesticides, fumigants, residual 
solvents, mycotoxins and microbial contaminants.29 On the other hand, phytochemical 
identification of herbal substances and preparations consists of chromatographic fingerprinting 
and quali-quantitative determination of selected constituents which represent the main or the 
most active components.  
From a legislative point of view, the Directive 2004/24/EC represented the first attempt 
made by the European Parliament to regulate and harmonize the legal status of plant 
preparations throughout the different European countries.31 The Directive establishes that 
herbal medicines released in the market need authorization by the national regulatory 
authorities of each European country and that these products must meet the acceptable level 
of safety and efficacy. The safety of herbal medicinal products is evaluated on the basis of 
existing scientific literature (data from clinical studies, case reports, pre-clinical studies). If data 
on safety are not sufficient, it will be communicated to consumers.32 According to these 
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criteria, two categories of herbal medicinal products have been established based on their 
efficacy/safety profile: well-established use herbal medicinal products (medicinal herbs with a 
recognized level of safety and efficacy) and traditional use herbal medicinal products. The last 
category include those medicinal herbs that do not have a recognized level of efficacy but are 
acceptably safe.33 Currently, after more than ten years since the introduction of the first 
European legislation on herbal medicines, over 1,300 plant-based products have been 
registered and more than 600 of them have been authorized for marketing on the basis of 
consolidated use in the EU Member States. EMA reports that today the sale of these medicines 
is accompanied by clear and harmonized information in all countries.34 Since its establishment, 
the Committee on Herbal Medicinal Products (HMPC) has issued 128 scientific opinions 
including monographs containing information on therapeutic use, contraindications, 
interactions with other drugs and potential side effects, based on the revision of all scientific 
data and historical information, with data on quality, efficacy and safety.34 These scientific 
opinions are used by the Member States of the Union to evaluate herbal medicine. The HMPC 
has also developed twenty guidelines to harmonize the registration and authorization 
processes of herbal medicines. Given their complexity, borderline cases such as plant products 
that fall into different product categories, are object of discussion in this context.  
Within the phyto-pharmaceuticals, the specific sub-category of medical devices requires a 
specific discussion. As a definition, medical devices include any instrument, apparatus, 
appliance, software, material or other article, whether used alone or in combination, including 
the software intended by its manufacturer to be used specifically for diagnostic and/or 
therapeutic purposes and necessary for its proper application, intended by the manufacturer to 
be used for human beings for the purpose of: 
 
● diagnosis, prevention, monitoring, treatment, or alleviation of disease; 
● diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap; 
● investigation, replacement or modification of the anatomy or of a physiological process; 
● control of conception; 
 
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological, or metabolic means, but which may be assisted in its function 
by such means (Directive 2007/47/EC).35 Despite the requirement to transpose the currently 
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directives (90/385/EEC, 93/42/EEC, 98/79/EC) into law in each Member State, the binding laws, 
decrees and ordinances of Member States led to differences in levels of requirements and in 
some cases to different approaches between Member States. As a result a variety of 
interpretations could be observed across the European Union, including different approval 
processes for clinical investigations, safety reporting during clinical investigations and not 
unified criteria for the classification of products.36 To solve these issues, two new Regulations 
on medical devices have been just approved on April 2017,37 thus replacing the existing 
Directives and creating a breaking point in the regulation of these products: 
 
 Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on 
medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and 
Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. 
 Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on 
in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission 
Decision 2010/227/EU. 
 
 The new rules will be apply after a transitional period of 3 and 5 years after entry into force 
on 25 May 2017, respectively for the Regulation on medical devices and on in vitro diagnostic 
medical devices.38 The aim of the new regulations is to ensure a better protection of public 
health and patient safety. Among the Regulation (EU) 2017/745, the approved text clearly 
defines the regulatory framework of “medical devices made of substances” and acknowledges 
that this product category is of utmost importance for the self-medication market. There are 
many aspects of the new regulation that will have a significant impact on the industrial system. 
These include the classification rule 21 and defining the concept of “absorption”, and clinical 
product evaluation. Medical devices are basically divided into four classes, ranging from low 
risk to high risk: I, IIa, IIb, III. According to the new rule 21, “devices that are composed of 
substances or of combinations of substances that are intended to be introduced into the 
human body via a body orifice or applied to the skin and that are absorbed by or locally 
dispersed in the human body are classified as: class III if they, or their products of metabolism, 
are systemically absorbed by the human body in order to achieve the intended purpose; class III 
if they achieve their intended purpose in the stomach or lower gastrointestinal tract and they, 
or their products of metabolism, are systemically absorbed by the human body; class IIa if they 
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are applied to the skin or if they are applied in the nasal or oral cavity as far as the pharynx, and 
achieve their intended purpose on those cavities; class IIb in all other cases” (Annex VIII, 
Chapter 3). When absorption is relevant for the intended purpose the classification is clear. 
However, all substance based medical devices, are somehow absorbed by the human body. In 
the absence of a clear criterion, a product containing substances generally recognized as safe 
and other active substances absorbed in concentrations not relevant for risk assessment would 
be classified in class III without any justification. Among others requirements of the new 
regulation there is the need to report on the label of devices that are composed of substances 
or combinations of substances, that are intended to be introduced into the human body via a 
body orifice or applied to the skin and that are absorbed by or locally dispersed in the human 
body, the overall qualitative composition of the device and quantitative information on the 
main constituent or constituents responsible for achieving the principal intended action” 
(Annex I, Chapter 3). In this view, the research into new analytical methods for the study of the 
composition of products containing natural complex substances and, if necessary, the 
application of ADME studies for the evaluation of plasma concentrations are required and an 
important role will be played by the combination of new emerging disciplines.  
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1.3 Metabolomics: a valuable tool to analyze natural complex matrices 
As discussed in the first paragraph, due to the concomitant presence of a multitude of 
different components, medicinal plants exert health effects as their whole rather than by virtue 
of a single component with the consequent occurrence of multi-target effects, mutual 
interaction among the components and synergistic phenomena. In this scenario, metabolomics 
is recently emerged as a valuable “omics” technology applied for the comprehensive profiling 
of the metabolome and aimed at identifying, quantifying and gathering detailed information 
about the complete set of metabolites present in a cell or organism (Figure 5).39 
 
 
Figure 5   ̶ The “pyramid of life” showing the varying influence of the environment and physiology on the 
genome, proteome and metabolome (extracted from lecture by David Wishart from University of 
Alberta - 2016 Informatics and Statistics for Metabolomics workshop) 
 
Since the metabolome refers to the complete set of small-molecules found within a 
biological sample as cells, cellular organelles, organs, tissues, biofluids or an entire organism,40 
metabolomics investigations on medicinal plants require the simultaneous analysis of a huge 
spectrum of compounds with very diverse physico-chemical properties. Accordingly, powerful 
analytical tools, able to cover a portion as widely as possible of the chemical space of plant 
metabolites, are required for the quali-quantitative determination of this vast array of 
chemicals. Currently, two main complementary approaches can be applied for metabolomics 
investigations, namely metabolic profiling (or targeted profiling) and metabolic fingerprinting 
(or non-targeted fingerprinting).41 Metabolic profiling focuses on the quantitative analysis of a 
group of metabolites related to a specific metabolic pathway or a class of compounds. While 
the metabolic profiling involves target analysis based on the direct measurements of selected 
analytes, the metabolic fingerprinting aims at comparing, rather than identifying, specific 
patterns or fingerprints of metabolites that change in response to disease, environmental or 
genetic perturbations.41 However, due to the high complexity and chemical diversity of the 
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metabolome, the simultaneous and comprehensive qualitative and quantitative analysis of all 
metabolites within a cell, tissue or organism still represents a fascinating challenge to face.42  
In this regard, a single analytical approach is generally not enough to provide a 
comprehensive overview of the metabolome but the combination of multiple and hyphenated 
techniques would be highly desirable.43 Accordingly, many analytical technologies have been 
employed to profile complex plant-derived matrices and the choice of the most suitable tool 
represents a compromise among speed, selectivity and sensitivity.44 Mass spectrometry (MS) 
and nuclear magnetic resonance (NMR) spectroscopy are the most commonly adopted 
analytical techniques to pursue this goal. NMR is one of the most efficient techniques for 
structure elucidation based on the measurement of specific molecular properties that can be 
associated with the molecular structure of known or unknown chemical entities.45 NMR is 
considered as non-biased technique that theoretically provides a unique signal for each 
chemically distinct nucleus responsive to the magnetic field. Despite its non-destructive feature 
and the possibility to easily set-up metabolic profiling platforms in high-throughput fashion, 
NMR-based approaches are characterized by a low sensitivity.46 Therefore, MS is by far the 
technology of choice for plant metabolomics studies,47 especially when coupled to powerful 
chromatographic techniques such as liquid chromatography (LC),48 gas chromatography (GC)49 
and capillary electrophoresis (CE).50 In particular, this paragraph will be mainly focused on the 
application of MS-based targeted and untargeted approaches for plant metabolomics studies 
through a typical workflow which includes the design of analytical experiments, followed by 
sample preparation, data acquisition, data processing and data analysis (Figure 6).51 
 
 
Figure 6   ̶  Typical MS-based metabolomics workflow. 
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Experimental design 
To ensure scientific soundness and robust conclusions to the metabolomic investigation, a 
rational design of the analytical experiment is required in order to prevent, or at least minimize, 
the occurrence of misleading factors of analytical origin that can garble the investigated 
variables. In other words, experimental design means providing the appropriate foresight to 
plan a study in order to guarantee that the variation observed in the study and related to the 
biological observations are significantly greater than process variability artificially introduced in 
the study. Thus, many experimental considerations are required, especially for the design of a 
large-scale study.52 These include, first of all, the reproducibility of sample collection, process 
and storage since differences in how samples are collected, processed and stored can strongly 
affect the observed metabolic profile. The design of multiple analytical experiments is often 
required, therefore large biological studies are generally divided into smaller analytical 
experiments to achieve an appropriate analysis of samples by controlling different factors. 
Among the most crucial factors to control, the number of injections within a single analytical 
session and the build-up of matrix and metabolites on LC and GC columns may cause variability 
in retention time data.52 Furthermore, the mass spectrometric performance represents an 
additional crucial factor which can lead to a different response of the analytes and m/z 
variability due to the aggregation of matrix components on the MS source or injector, thus 
affecting the ion transmission from atmospheric to vacuum regions of the mass spectrometer. 
Another expedient is based on the randomization during sample preparation and data 
acquisition to ensure that no bias is introduced. Moreover, between two analytical sessions it is 
important to return the instrument to the optimal performance by cleaning the LC column and 
the MS source to remove contaminants and tuning the mass spectrometer. Due to the 
numerous sources of analytical variability in MS-based analytical methods, a pragmatic 
approach for monitoring data quality is based on the use of quality control (QC) sample, 
prepared from the sample under analysis and analyzed at regular intervals throughout the 
analysis.52 Being representative of the qualitative and quantitative composition of the samples 
under investigation, QC samples can be applied to chromatographic conditions and MS 
instruments following maintenance, in order to correct small levels of variation, to 
quantitatively measure technical reproducibility and to integrate data from different analytical 
experiments. Internal standards spiked into samples is another method that can be applied to 
reduce sample variability, in particular when an isotopic analogue of the metabolite under 
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investigation is used. However, the use of an internal standard for each metabolite to be 
detected in a complex plant extract is difficult to apply because of the large number of 
standards required, the cost of purchasing isotopic analogues for each metabolite and the 
limited qualitative knowledge related to metabolome composition before sample preparation 
and data acquisition. In this regard, the use of a single internal standard can be applied to 
correct analytical variation for a group of metabolites that are either chemically related or 
unrelated.52 
 
 
Sample preparation 
Sampling and sample preparation are fundamental steps to prevent any biochemical process 
able to degrade the target metabolites or to generate new artifacts, thus avoiding any change 
in the metabolites concentration and identity.53 The main methods used for quenching the 
enzymatic activity in plant matrices are represented by freeze clamping, immediate freezing in 
liquid nitrogen and acidic treatments. Concerning the sample preparation, the ideal protocol 
must allow the analytes extraction from complex biological matrices, making them compatible 
with the analytical technique while removing at the same time those components able to 
interfere with the analysis. However, the adopted protocol for the sample preparation can be 
different depending on the type of metabolomic analysis. For example, in target metabolic 
analysis, since the metabolites are known, the sample preparation can be specifically addressed 
for the target analytes, while the ideal sample preparation protocol for untargeted approaches 
should be as aspecific and universal as possible with minimum analytes losses.53,54 The main 
techniques for sample preparation include: 
 
 Solid-phase extraction (SPE): This technique, widely used in targeted and profiling analysis 
to eliminate the interfering matrix, aims to extract analytes from biological fluids. SPE is 
based on the temporary retention of the target metabolites from a flowing liquid sample 
on a solid sorbent. The retained analytes are then eluted from the sorbent by using a 
solvent of suitable elution strength.55 
 
 Liquid-liquid extraction (LLE): Mainly used for tissue extraction by shaking or vortexing the 
matrix with organic solvents after the fine grinding of the frozen sample.56 The solvents 
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used are isopropanol, ethanol, methanol, acetonitrile, water, water/methanol for polar 
compounds, while more lipophilic metabolites can be extracted with chloroform or ethyl 
acetate. The simultaneous use of polar and apolar solvents allows the fractionated sorting 
of metabolites into polar aqueous and lipophilic organic fractions which can be separately 
analyzed.57 Recent variants of this technique include ultrasound-assisted extraction (UAE), 
microwave-assisted extraction (MAE), extraction with ionic liquids, supercritical fluid 
extraction (SFE) and accelerated or pressurized solvent extraction (ASE).58 
 
 Direct injection: This approach involves the simple dilution and the direct injection of the 
sample without any prior manipulation.59 Although is a fast analytical approach in which 
complex mixtures are often resolved into components differing in ion mass, avoiding time-
consuming chromatographic separation, direct infusion mass spectrometry (DIMS) suffers 
from drawbacks such as ion suppression and adduct formation phenomena due to the 
high-salt content and the contamination of the non-volatile residues with rapid reduction 
of the instrument performance.60 The resulting ion intensity profiles are typically analyzed 
by multivariate statistics to identify key ions discriminating classes of samples.59 
 
 
Sample analysis 
Modern MS offers a vast set of technologies that differ in operational principles and 
performance, including different ionization techniques, mass analyzers, resolving power and 
mass accuracy.61 The most common ionization techniques in metabolomics are electron 
ionization (EI), electrospray ionization (ESI) and atmospheric pressure chemical ionization 
(APCI).61 ESI and APCI are the most common employed in LC-MS-based metabolomics: the 
former is well suited for the ionization of a wide range of metabolites including drug 
compounds, aminoacids, organic acids, sugars, steroids, phospholipids and fatty acids; the 
latter is used especially for the ionization of non-polar compounds such as phospholipids, fatty 
acids, steroids and essential oils. Mass analyzers with different resolving power are also 
employed in metabolomics. These include quadrupole (Q) and triple quadrupole (QQQ), the 
time of flight (TOF), quadrupole-time of flight (Q-TOF) and ion trap (IT) (Table 4 and Figure 7). 
Each of these has different advantages and disadvantages and range of applicability that 
depend on the specific metabolomics area.51 
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Table 4  ̶  Overview of the most commonly used mass spectrometers for metabolomics applications.51 
a 
Internal calibration. 
b
 External calibration. 
 
 
 
 
 
Mass analyzer 
 type 
Resolving power  
(FWHM) 
Mass accuracy  
(ppm) 
Scan rate Mass range 
Dynamic  
range 
Low resolution instruments 
QqQ 
Up to 7,500  
(at m/z 508) 
5-500 ppm Up to ~ 5,000Da/s Up to 3,000 m/z 10
5
-10
6
 
IT/LIT Up to 10,000 50-500 ppm Up to ~ 33,000Da/s Up to 4,000 m/z 10
4
 
Qq-LIT 
Up to 9,200  
(at m/z 922) 
50-500 ppm Up to ~ 20,000Da/s Up to 2,000 m/z 10
5
-10
6
 
High resolution instruments 
TOF  
Up to ~20,000 
(at ~m/z 1,000) 
< 1-2 ppm
a
 Up to 40 Hz Up to 20,000 m/z 10
4
-10
5
 
Qq-TOF 
Up to 60,000 
(at m/z 1,222) 
< 1-2 ppm
a
 Up to 100 Hz Up to 40,000 m/z 10
4
-10
5
 
IT-TOF 
10,000 
(at m/z 1,000) 
< 2 ppm
a
 10 Hz Up to 5,000 m/z 10
3
 
Orbitrap-
Exactive 
Up to 140,000 
(at m/z 200) 
< 1 ppm
a 
< 3 ppm
b
 
Up to 12 Hz with a 
mass resolution of 
17,500 (at m/z 200) 
Up to 6,000 m/z 10
3
-10
4
 
LTQ-Orbitrap 
Up to 240,000 
(at m/z 400) 
< 1 ppm
a 
< 3 ppm
b
 
Up to ~8 Hz with a 
mass resolution of 
15,000 (at m/z 400) 
Up to 4,000 m/z 10
3
-10
4
 
Q-Orbitrap 
Up to 140,000 
(at m/z 200) 
< 1 ppm
a 
< 5 ppm
b
 
Up to 12 Hz with a 
mass resolution of 
17,500 (at m/z 200) 
Up to 4,000 m/z 10
3
-10
4
 
LTQ-FT 7T 
>750,000 
(at m/z 400) 
< 1 ppm
a 
< 1.2 ppm
b
 
1 Hz with a mass 
resolution of 100,000 
(at m/z 400) 
Up to 4,000 m/z 10
3
-10
4
 
Qq-FT 7T 
> 1,000,000 
(at m/z 400) 
< 1 ppm
a
 
< 1.5 ppm
b
 
1 Hz with a mass 
resolution of 250,000 
(at m/z 400) 
Up to 10,000 m/z 10
3
-10
4
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Figure 7  ̶  Schematic representation of some mass spectrometry analyzers: ion trap (A), Q-TOF (B) and 
triple quadrupole (C). 
 
For example, quadrupole-based analyzers are particularly appropriate for quantitative 
analysis, while TOF analyzers have greater scan speed, dynamic range and sensitivity, allowing 
the quantitative profiling over a wider range of metabolite concentrations and the detection of 
lower concentrations. For the analysis of extremely low concentrated metabolites, an IT-based 
instrument would be the most suited, allowing the trapping of specific ions. MS/MS or MSn-
analyzers are required for compounds identification. Q-TOF, QQQ and conventional IT have 
been commonly employed to perform MS/MS within plant metabolomics for the identification 
of a broad range of phytochemical species, although conventional MSn-analyzers lack mass 
accuracy if compared with the more recent technologies such as Fourier transform ion 
cyclotron resonance MS (FT-ICR-MS) and linear trap quadrupole orbitrap MS (LTQ-Orbitrap 
MS). Recently, Q-TOF technology has prompted a great deal of interest thanks to the 
development of higher sensitivity analyzers able for accurate quantitative profiling together 
with the possibility to filter specific ranges of mass ions within the quadrupole and collision-
induced decomposition (CID) for structural analysis via fragmentation. Modern Q-TOF/MS 
instruments also allow the simultaneous collection of two functions of data within a single run: 
one is performed at low energy in order to extrapolate the exact precursor ion mass spectra 
while the other is acquired at higher energy to provide the exact mass of the fragment ions. 
Thus, for each chromatographic peak, both MS quantitative profiling data and MS/MS 
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fragmentation data for compounds identification can be acquired.62 Among the different MS-
based metabolomics techniques, we can distinguish direct MS analysis and MS coupled to 
chromatography.61 MS coupled with chromatographic techniques represents an excellent 
solution for complex mixture analyses with several advantages including the reduction of 
matrix effect and ion suppression phenomena, isomers separation, more accurate 
quantification of single metabolites.61 Currently, two main chromatographic techniques have 
been coupled with MS for plant metabolomics investigations: 
 
 Gas chromatography coupled to MS (GC-MS): This technique is ideally suited for the 
 analysis of volatile and thermally stable compounds. These include ketones, aldehydes, 
 alcohols, esters, furan, pyrrole derivatives and other heterocyclic compounds. If the 
 analytes under analysis are not sufficiently volatile, a derivatization step is previously 
 required. GC-MS is used in metabolome analysis thanks to its high separation efficiency 
 due to the use of modern capillary columns that enable the separation of more than 100 
 compounds in a single analysis by an accurate selection of the capillary column, the 
 stationary phase and the film thickness. In addition, the standardized MS electron 
 ionization energy of 70 eV leads to reproducible mass spectra and highly transferable 
 electron ionization MS spectral libraries that allows compounds identification through mass 
 spectral library matching.61 GC is often coupled to single quadrupole MS detector which 
 has the advantages of high sensitivity and good dynamic range although suffers from 
 slower scan rates and lower mass accuracy. GC-triple quadrupole MS/MS is capable of 
 multiple reaction monitoring of analytes, which can overcome the identification and 
 quantification problems associated with co-eluting compounds in complex matrices. GC-
 TOF-MS technology offers high mass resolution, high mass accuracy and fast scan speeds.61 
 
 Liquid chromatography coupled to MS (LC-MS): This technique is generally used for 
molecular identification and quantification of polar, less-polar and neutral metabolites. It is 
particularly valuable for target analysis thanks to its resolving power, sensitivity and 
specificity, allowing the identification of target metabolites in very complex matrices. 
Reversed-phase (RP) columns such as C18 and C8 are the most utilized. LC-MSn represents 
the most important tool for the identification of metabolites in crude plant extracts, 
providing not only molecular mass information but also structure information deduced 
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from fragmentation patterns deriving from the collision-induced dissociation. LC-MS 
represents also an important technique for metabolic fingerprinting thanks to the 
possibility to detect known and unknown compounds which can be identify without any 
prior knowledge of their exact chemical structure.63 In particular, ESI, APCI and fast atom 
bombardment (FAB) have been used as ionization techniques for the MS analysis of plant 
metabolites in combination with RP-LC.63 
 
Data analysis 
Metabolomics raw data are a source of information and, in turn, a great source of 
knowledge after suitable data processing. In this regard, the ability to mine big data and to 
undertake reliable comparative analysis governs the success of metabolomic-based 
experiments.46,64 Depending on the approach used, metabolomic data can be submitted to 
different purposes.  
When the goal of the metabolomic analysis is to determine the relative differences between 
the metabolomes of two or more systems, data analysis is largely carried out by using 
chemometric tools.65 Accordingly to Goodacre et al.,65 after the acquisition of mass spectra, the 
data sets require a pre-processing step, which includes the reduction of background noise, 
adjusting for baseline shifts and machine drift, peak alignment, peak detection and mass 
spectra deconvolution (the separation of overlapping signals into individual chemical peaks).66 
Statistical analysis is then applied to the data set to extract biological relevant information by 
using an appropriate algorithm or a set of algorithms. Univariate analysis is the simplest 
statistical method and is carried out with only one variable at a time (ANOVA, t-tests, etc).  
Although metabolomics experiments generate multivariate data, univariate methods can be 
employed to test individually metabolites that are increased or decreased significantly between 
different groups. Multivariate data analysis (MVDA) treats, instead, the analysis of multiple 
variables simultaneously and includes both unsupervised classification methods, such as 
principal component analysis (PCA) and hierarchical cluster analysis (HCA), and supervised 
approaches such as partial least square (PLS) for metabolites classification.67 In particular, PCA 
provides a rapid means for the visualization and comparison of data sets and can be used to 
classify different sample groups and to provide information about the variance in the data, with 
minimal loss of information. In fact, the concept behind PCA is to describe the variance of a set 
of multivariate data in terms of a set of underlying orthogonal variables, namely principal 
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components (PCs). The original variables can be expressed as a particular linear combination of 
PCs, with each PC accounting for a portion of the total variance of the data set. HCA is a method 
of grouping samples in a data set by their similarity. On the contrary, PLS is a MVDA technique 
that allows sample discrimination by reduction of dimensionality and maximizing correlation 
between variables.  
Thousands of metabolites can be detected by applying untargeted approaches, with limited 
prior knowledge of the sample composition.68 In this regard, the Metabolomics Standard 
Initiative (MSI)69 has published several guidelines on metabolomics experiments and analysis 
including several levels of identification with various levels of confidence: 
 
1. Identified compounds: known compounds identified by comparing retention time and mass 
spectrum, or retention time and NMR spectrum, or exact mass and MS/MS, or exact mass 
and isotope pattern with authentic compounds under identical analytical condition. 
2. Putatively annotated compounds: identified without chemical reference standards, based 
upon physicochemical properties and/or spectral similarity with public/commercial spectral 
libraries. 
3. Putatively characterized compounds: the identification is based on the characteristic 
physicochemical properties of a chemical class of compounds, or by spectral similarity to 
known compounds of a chemical class. 
4. Unknown compounds: although unidentified or unclassified, these metabolites can still be 
differentiated and quantified based upon spectral data. 
 
However, despite the relative high level of information available for a specific compound, its 
accurate identification may be sometimes difficult. For example stereoisomers appear very 
similar based on their chromatographic or mass spectrometric profile, especially in non-
optimized analytical methods commonly applied for untargeted metabolomic studies: thus, in 
such cases, the development of chromatographic methods for the unequivocally resolution of 
the isomeric mixture is mandatory. The first step for compounds identification using MS 
platforms is based on the accurate measurement of the m/z. After the identification of one or 
more possible molecular formulas by using available compound libraries such as KEGG, 
PubChem or ChemSpider, the matching to known metabolites is generally performed.68,70 
Thanks to the availability of fragments from MS2 or MSn, the possible elemental composition 
1.   Introduction 
- 26 - 
can be restricted since fragmentation lead to characteristic fragment ions for each molecular 
formula, helping to generate hypothesis about completely unknown compounds.71 In LC-MS, in 
silico fragmentation software are available to enable the matching of in silico derived mass 
spectra (instead of mass spectra derived from authentic chemical standards) to the 
experimentally derived mass spectra. The comparison of tandem mass spectra against 
measurements from literature or database allows to keep the putatively annotated 
compounds. Once the MS2 or MSn mass spectra are available, they can be compared with 
reference spectra available in several public libraries.  
The Human Metabolome Database (HMDB) contains information about 8,500 compounds 
and 10% of them have MS2 data available.72 The Metlin database contains information about 
44,000 metabolites and for 10% of them high-resolution MS2 spectra are available.73 Finally, 
MassBank represents the first public mass spectral database that accept spectral data from the 
community. Both HMDB and Metlin do not possess a good coverage of plant-specific 
metabolites, while on the other side, MassBank provides a much better coverage of secondary 
plant metabolites.74 The comparison of experimental data (accurate m/z, retention time, 
fragmentation mass spectrum) for each metabolite to mass spectral libraries constructed with 
authentic chemical standards is the ideal process to provide definitive identification. This is 
currently more successfully achieved for data acquired on GC-MS platforms compared to LC-MS 
platforms, but the growing number of spectra of a variety of instruments will help to overcome 
the old problem that soft ionization spectra are less reproducible than those generated by GC-
EI-MS. Without metabolites identification it is impossible to base biological reasoning on the 
datasets.68  
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Aboca’s research is focused on the investigation of novel natural biologically-active 
substances, transformed by physical technological processes that use water and ethanol as 
extraction solvents while avoiding any unnecessary additives.75 The application of hyphenated 
techniques, modern tools in molecular biology and analytical platforms for the quali-
quantitative and biological characterization of natural complex products is the basis of the 
scientific research in Aboca S.p.a., which is aimed not only to enable the use of natural products 
to treat symptoms of common human minor disorders but also to gain new pharmacological 
knowledge leading to the primary objective of restoring the body’s equilibrium. Furthermore, 
the unrelenting progress in the "omics" disciplines will help, even more in the near future, in 
evaluating the correspondence between the patterns of highly complex natural-derived APIs 
and the physio-phatological pathways in human body. Aboca’s philosophy believes that the 
scientific knowledge available today allows us to rationalize a more systemic vision of 
humankind and its interactions, even with complex substances such as those found in nature. In 
other words, according to the so-called holistic vision, the sum of the parts is more functional 
than the sum of the performance of the individual parts.  
When applied to the phytochemical field, the holistic model allows to investigate natural 
complex systems by an inter- and multidisciplinary method and to understand how the activity 
of a plant complex could be different, and sometimes greater, with respect to the single 
isolated components.  
Based on these considerations and according to this "mission", more than ten years ago the 
Phytochemical Research Unit was established in Aboca S.p.a. (Sansepolcro, Italy) with the aim 
to investigate formulated natural complex products by using hyphenated analytical techniques 
including LC-MS, GC-MS, ICP-MS, LC-DAD, LC-RID.  
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As a part of this research interest,76 the following chapter of this Philosophiae Doctor Thesis 
describes the application of two complementary mass spectrometry-based approaches for the 
metabolomics investigation of Grintuss® syrup, a medical device based on honey and functional 
vegetable substances (resins, polysaccharides and flavonoids from Grindelia robusta, Plantago 
lanceolata and Helychrisum italicum) which creates a protective film with a "barrier effect" that 
soothes the cough and protects the upper respiratory tract.77  
The first approach, based on an untargeted fingerprinting, was aimed to obtain a broad 
picture of the whole metabolome of Grintuss® syrup by detecting as many groups of 
metabolites as possible, without identifying nor quantifying. Thus, focussing on the whole 
formulation rather than on the single components, this approach allowed the generation of a 
sort of “identity card”, namely multivariate control chart, useful to assess the quality end-points 
and to compare the biological uniformity among different batches of the production supply 
chain by finding statistically significant biomarkers. 
On the other hand, a LC-MS-based metabolomic profiling approach have been successfully 
developed and applied for the quali-quantitative analysis of GrinTuss® syrup by matching the 
detected metabolites with standard reference compounds deriving from an in-house database 
specifically built.  
Although the work presented in this PhD Dissertation has been mainly focussed on the 
application of LC-MS protocols, it is a part of a larger multidisciplinary project aimed at 
achieving the comprehensive knowledge of the whole quali-quantitative profile of natural 
complex products by combining different analytical facilities. Thus, the investigation disclosed 
as well as the results achieved within this Doctoral work should be considered as a preliminary 
exploratory attempt to face the fascinating challenge to guarantee the quality, efficacy and 
safety of phytochemicals rather than an exhaustive dissertation on the topic. 
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2 Results and Discussion 
 
 
 
 
 
2.1 On the way to a validated untargeted metabolomics approach for monitoring the batch-
quality compliance of Grintuss® syrup 
According to the holistic approach and starting from the general assumption that several 
metabolites may contribute to the whole activity of natural complex products, in the first part 
of this Thesis the biological uniformity among different batches within the production supply 
chain of formulated natural complex products, has been investigated by focussing on the whole 
formulation rather than on the single components. In particular, with the aim to overcome 
reproducibility issues associated with the traditional untargeted MS-based metabolomics 
analysis, in this study a multivariate statistical process control (MSPC) for monitoring the batch-
quality of Grintuss® adult syrup has been successfully adopted. As previously discussed, the 
purpose of non-targeted metabolomics studies is to find statistically significant biomarkers 
through unbiased differential analysis of as many signals as possible deriving from the biological 
sample under investigation. In particular, within phytochemical untargeted investigations of 
complex natural products, the main task is to highlight those attributes accounting for the 
standard quality manufacturing of the formulated product without the need to identify at 
which metabolites these biomarkers correspond. In both cases, the comparison will be 
statistically valid only whether all the samples are analyzed under the same experimental 
conditions using a robust analytical method and whether the change observed in the 
metabolomic profile can be unquestionably related to variations in the concentration of specific 
biomarkers object of the investigation.78 Although exhaustive guidelines for the validation of 
non-targeted approaches are still not available, the main validation strategies currently 
adopted in such investigations involve the use of quality control samples (QCs),52,79 spiked 
standards80 and statistical model validation.64,65,81 Besides the efforts to set up a unique 
validation protocol, the MSI is defining the criteria for the standardization of data reporting in 
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order to make the data readily available to others for evaluation, support an extension or 
repeat of the work as desired.82 In pursuing this aim, the workflow adopted involved the 
preliminary sample preparation followed by its direct infusion through flow injection into a 
mass spectrometer endowed with an ESI interface and an ion trap as analyzer. In this regard, 
within the untargeted approach, the direct infusion via flow injection electrospray ionization 
mass spectrometry analysis (FIA-ESI-MS) of whole formulated natural complex products allows 
to avoid any prior chromatographic separation thus providing a huge set of data in high-
throughput fashion. On the other hand, especially for large scale multi-batches experiments, 
analytical variability in automated direct infusion mass spectrometry (DIMS) metabolomics 
analysis, as FIA-ESI-MS, is a well-known issue since hundred of metabolites are simultaneously 
measured in a single experiment.83 For this reason, the use of a metabolomics analysis for 
quality evaluation of complex natural products batches through different years of production is 
a challenging task. To face this challenge, a specific data processing procedure, based on the 
building of multivariate control charts, was applied. Thus, after having assessed the validity of 
the model using the multivariate control charts, the quality verification of a new batch under 
investigation was achieved by comparing its profile with the fingerprinting profile of batches 
prepared according to the optimized manufacturing process and validated by the traditional 
continuous quality control throughout the production chain (selected as model of “good” 
quality batches) and the profile of batches deriving from pre-established production errors 
(selected as model of batches of “poor” quality). In order to correctly compare samples 
analyzed within different experimental sessions, the use of the so called golden standard (GS) 
sample, a sample being endowed with the same quali-quantitative composition of the samples 
to be analyzed, was required together with a robust method for data alignment. 
 
Experimental design 
As the first step, one year of production (from April 2014 to May 2015) of Grintuss® adult 
syrup formulation was monitored to design the experiment. In particular, a total of 24 samples, 
each one corresponding to a different batch of production, was collected and of these, 6 
batches were used as the test set while 18 were used to build the control chart. Moreover, 
within the test set, 3 samples, indicated as t4-t6, were specifically produced in laboratory by 
using a deliberately wrong composition in order to reproduce the profile of batches deriving 
from production errors and were therefore used as model of “poor” quality products.  
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In particular, “poor” quality batches were obtained by preparing Grintuss® adult syrup 
formulation with a wrong relative ratio of both the sugary component and the active freeze-
dried extracts (Table 5, entry 1, sample t4) and without the active freeze-dried extracts (Table 
5, entries 2 and 3, samples t5 and t6). On the other hand, the training set (18 samples) was 
used to reproduce the profile of “good” quality batches prepared according to the optimized 
manufacturing protocol (according to the GMP) and submitted to the standardized quality 
control operations. All the samples were prepared, preliminary analyzed and stored at -80 °C 
before performing the analysis. Thus, a preliminary data analysis of the training set based on 
the PCA allowed to identify the most suitable GS to be used in the experimental sessions. In 
particular, the GS was selected as the closest sample to the centre of the PCA score space for 
being the most representative sample of the training set. Thus GS, prepared according to the 
other samples and stored at -80 °C, was analyzed together with samples under investigation in 
different analytical sessions to monitor the instrumental variability.  
 
Table 5  ̶  Quali-quantitative composition of “poor” quality batches of Grintuss® adult syrup. 
 
Sample preparation 
0.5 g of each sample were solubilised in ethanol/water (100 mL, 50:50 w/w). The solution 
obtained was analyzed, without further dilution, to achieve a signal intensity of 105-106. After 
the preliminary analysis, for the choose of the GS, an aliquot of each solution was stored at -80 
°C. 
 
Entry Sample Composition 
1 t4 
Deionized  water (81%), honey (15.57%), lemon juice (1.25%), essential oils (0.67%), 
Plantain mother tincture (0.67%), Curry plant (Helichrysum italicum) freeze dried 
extract (0.53%), Gumweed (Grindelia robusta) freeze dried extract (0.17%), Plantain 
(Plantago lanceolata) freeze dried extract (0.15%). 
2 t5 Honey (81%), deionized water (19%) 
3 t6 Brown sugar (50%), deionized water (25%), honey (25%) 
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FIA-ESI-MS analysis 
The collected samples were thus analyzed in 11 different analytical sessions, with the test 
set corresponding to the last session. In all the sessions, experiments were run in triplicate with 
randomized run order while GS samples were run in regular positions within each analytical 
session. FIA-ESI-MS analysis was carried out in a HPLC system and the outcome was analyzed by 
an ion trap mass spectrometer equipped with an ESI interface operating in negative ion mode. 
Different mobile phases were tested (data not shown) and the mixture methanol/water 50:50 
(v/v) was finally chosen as the best mobile phase in terms of analytical performance. Thus, the 
mobile phase consisted of methanol (A) and ultrapure water (B) according the following 
elution: 0-5 min A/B 50:50 (v/v). Before injecting a new sample, the system was equilibrated for 
20 minutes by pumping the mixture A/B (50:50, v/v) as washing solvent. The flow rate was set-
up to 0.2 mL min-1 with an injector volume of 5 µL. In absence of the column, the injection of 
the sample using the HPLC pump generated a peak that eluted between 0.05 min and 5.0 min, 
and this delay corresponds to the time required to the signal to return to the baseline.  
 
Data processing  
Different sources of variability may affect the data sets produced by FIA-ESI-MS with the 
result to cover the biological diversity of the collected samples. In particular, while the 
biological variability represents the key point for comparing the quality of different samples, 
the instrumental variability represents a critical aspect to be controlled and minimized. In this 
regard, in order to produce fingerprints and multivariate control charts able to bring out only 
the biological variability among the samples while minimizing the instrumental variability, 
specific procedures were applied. These include the randomized run sequences with GS and 
blank samples, calibration procedures for the detector and the use of suitable tools for data 
pre-processing and pre-treatment. Firstly, the data acquired were peak picked and, within each 
experimental session, the background was subtracted to the corresponding sample using 
Subtract View Spectrum as Background routine of the Data Analysis software (trap version 3.3, 
Bruker Daltonik GmbH). A typical Grintuss® adult syrup fingerprint mass spectrum background 
subtracted is depicted in Figure 8. As a result, for each sample a peak list with m/z values and 
the corresponding peak intensity was generated. 
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Figure 8  ̶  Grintuss® adult syrup fingerprint mass spectrum background subtracted. 
 
 
Since the analysis of the collected samples generate peak lists in which the same metabolite 
may exert different m/z values depending on the mass accuracy and the resolution of the mass 
spectrometer, a data matching procedure was required to match the corresponding peaks in 
the obtained peak lists (data pre-treatment). The result of the peak list matching was a data 
table having the sample representation in terms of peak intensity in rows and the 
corresponding m/z in columns for each detected metabolite. Peaks detected in different 
samples were matched through the calculation of a suitable match score (Equation 1).  
 
djiij master m/zm/z1score   
(Equation 1) 
 
where m/zi is the m/z value for the peak i to be matched, m/zmasterj is the m/z value of the peak 
j of the master peak list and d the m/z tolerance.  
 
The master peak list was defined as the list containing all the detected peaks represented by 
the mean of m/z values calculated for the samples showing that peak. Due to the m/z 
resolution of the mass detector used in this study, d= 0.8 was considered. The algorithm used 
for matching the peaks takes one peak from a peak list at time and matches the peak to either 
the best matching peak of the master peak list, or appends a new peak to the master peak list if 
matching is not found for the peak. The best matching is calculated on the basis of the match 
score while the m/z value of the master peak list is updated by mean calculation if the matching 
is found. The algorithm can be summarized as the following 4 steps:  
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1. The master peak list is initially set to the peak list of the first sample; 
2. The peak list of the second sample is compared with the master peak list. For each peak of 
 the peak list the match score is calculated and, on the basis of the best score, each peak is 
 matched to a peak of the master peak list or added as new peak of the master peak list if the 
 score is zero; 
3. The m/z values of the master peak list are updated on the basis of the matched peaks; 
4. Steps 2 and 3 are iterated thus including the other samples one at time.  
 
This procedure generates a master peak list and a data table containing all the matched 
samples. When a new sample requires to be matched, step 2 of the algorithm is iteratively 
repeated without the updating step of the master peak list. Peaks showing match score equal 
to zero are automatically excluded from the data table and separately investigated to highlight 
the presence of potential contaminants. Since the master peak list could reflect the order of the 
samples used during the peak list matching procedure, a specific strategy was adopted to 
define the order of the samples to be used. In particular, a first data matching was performed 
by using a m/z tolerance equal to 2. The obtained data table was then centered on the mean 
and submitted to PCA considering 3 PCs. As a result, a ranking for the samples was defined 
according to the increasing distance to the centre of the PCA score space. The sample closest to 
the centre was used as the starting point for peak list matching (step 1) while the obtained 
ranking defined the order to use. The procedure was repeated until the convergence of the list 
to the ranking. Furthermore, if a matching peak is not found in some of the peak lists, the 
resulting data table may contain empty gaps. In this case, to reduce the number of gaps in the 
resulting data table, and then to minimize the influence of missing data in the control charts, 
only metabolites detected in more than 90% of the samples in the calculation of the master 
peak list were taken into account. The master peak list was built considering only the GS 
included in the training set. As a result, a master list composed of 529 peaks was obtained. For 
data normalization, the following expression for the intensity ÎikJ in the matched peak list was 
considered (Equation 2). 
 
ikJiJkikJ   IIˆ  (Equation 2) 
where IiJ is the intensity of the metabolite i in the sample J, k is a factor depending on the 
experimental run k and ikJ is the background random noise.  
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The effect of the random noise (ikJ) was reduced by calculating the median of the 3 
replicates of each sample within the same experimental session while the effect of k was 
taken into account applying the Median Fold Change (MFC) normalization on the GS injections. 
In this regard, since the GS was run in all the different experimental sessions and different 
times within the same experimental session, it was possible to estimate k and therefore to 
normalize the data following a two-steps procedure. Thus, after having select a run of the GS as 
a reference, the ratio between the intensity measured for a specific run of the GS and the 
intensity of the reference was calculated for each variable of the master peak list and, finally, 
the median of the all fold changes was obtained. The median was then used to normalize all the 
samples nearest to the considered GS. The procedure was repeated for each run of the GS. It is 
worth of note that the GS selected as the reference does not affect the performance of the 
obtained control charts since different references produce data sets with a different factor 
scale without modifying the topology of the latent space. 
 
 
Data analysis  
After peak list matching, median of the replicates and MFC normalization, each sample 
resulted to be described by the same set of variables. The obtained representation was 
submitted to a multivariate data analysis by PCA to compare the features characterizing 
batches of “good” quality with respect to batches of "poor" quality.84 To gain a deeper 
understanding of these differences, latent variables derived by PCA, the residuals of the model 
or suitable combinations of scores and residuals such as DModX+ (i.e. the distance to the model 
augmented with a term that measures how far projection of the observation falls outside with 
respect to the acceptable model domain) can be displayed by control charts.85 This enables the 
specification of multivariate control limits, rather than control limits connected to univariate 
control charts of the single measured variables. Data were mean centered and Pareto scaled 
before performing data analysis. Multivariate statistical data analysis was performed by 
SIMCA13 (Umetrics, Umea, Sweden) while data pre-treatment was applied by R-functions 
developed within the platform R 3.0.2 (R Foundation for Statistical Computing). 
 
 
 
2.   Results and Discussion 
- 36 - 
Results  
In order to reduce the analytical variability within different analytical sessions and to obtain 
control charts where the biological source of variation among the samples can be easily 
highlighted, in this study we introduced the use of GS samples in each experimental session and 
a suitable data pre-treatment based on the information collected in different analytical 
sessions. In particular, with the aim to reduce the performance decay of the ion source during 
the experiments, locked master peak list was used for matching the samples while the median 
of the replicates was applied to remove the effect of the random noise. Finally, data 
normalization based on MFC was performed on the GS to estimate the factor k specifying the 
response of the detector for each run. 
As a result, the data set obtained was composed by 116 analytical runs (24 samples × 3 
replicates + 44 GS runs) and 529 m/z variables. To highlight the effects of the proposed 
procedure for data pre-treatment, we firstly reported the investigation of the data set before 
calculating the master peak list by considering only the GS, the median of the replicates and 
applying data normalization. The obtained PCA model showed 2 PCs (R2= 0.75, Q2CV7-folds= 0.68) 
(Figure 9).  
 
 
Figure 9  ̶  PCA score scatter plot of the collected samples coloured according to the experimental 
session (R2= 0.75). Stars indicate the GSs while samples are depicted as circles. 
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From the inspection of the PCA score plot it is possible to observe how the GS sample runs 
span a larger space with respect to the regions occupied by other samples as indicated by the 
fact that the variance of the X-block related to GS is 0.85 times than the variance of the other 
samples (Figure 9). In other words, since the GS sample runs correspond to the same sample, 
the variability produced in the data by the different experimental sessions has the same 
magnitude of the variability arising from the biological diversity among the samples. To reduce 
the effects of the experimental session, the pre-treatment procedure described above was 
applied. After the calculation of the master peak list considering only the GS, the median of the 
replicates and MFC normalization on the GS, the PCA model showed 2 PCs (R2= 0.52, Q2CV7-folds= 
-0.0077) (Figure 10).  
 
 
Figure 10  ̶  PCA score scatter plot of the collected samples after data processing coloured according to 
the experimental session (R2= 0.52). Stars indicate the GSs while samples are depicted as circles. 
 
As depicted in Figure 10, after data processing the GS runs are more closed to each other 
with respect to the previous PCA score plot (Figure 9) and the effects due to the experimental 
session are strongly suppressed as demonstrated by the fact that the variance of the X-block 
related to GS is 0.15 times than the variance of the other samples. Thus, the control chart for 
MSPC was built on the basis of the PCA model of the data set composed of the 18 samples 
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representing batches of “good” quality. The PCA model showed 3 PCs (R2= 0.63, Q2CV7-folds= 
0.26). The test set composed of the last 6 produced batches was projected on the PCA model in 
order to extrapolate useful parameters for evaluating the compliance of the samples under 
investigation with respect to the batches defined of “good” quality. On the basis of the 
DModX+ control chart with a control limit equal to 99%, 3 batches resulted compliant while 3 
batches resulted outlier. Interestingly, since the batches that resulted not compliant 
correspond to those specifically produced in laboratory by using a deliberately wrong 
formulation composition, we can conclude that the use of multivariate control charts allowed 
to endorse “good” quality batches while discriminating batches of “poor” quality (Figure 11). 
 
 
Figure 11  ̶  DModX+ control chart (control limit equal to 99%). In red are reported the DModX+ of the 
samples of the training set (from C1 to C18) while in blue the DModX+ of the predicted samples (last 6 
batches of production from t1 to t6). 
 
The multivariate control chart used in this study allowed to investigate complex correlation 
structures within the samples that cannot be highlighted by classical univariate approach. As an 
additional goal, univariate data analysis based on the traditional control charts was further 
implemented in order to disclose significant variations in each single variable. Thus, although 
univariate control charts confirmed the conclusion of the multivariate control charts, it should 
be noted that in the multivariate case the DModX+ control chart is able to summarize the 
effects included in more than 500 univariate control charts. Moreover, also the part of the peak 
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list of the new samples to be investigated not included in the master peak list must be analyzed 
to evaluate the risk of poor quality batches. Usually, the number of these peaks is limited 
making the manual check not time consuming. In our study, peaks corresponding to the 
metabolites not included in the master peak list were around 15, accounting for only 2% of the 
total number of recorded signals, while in more than 80% of the samples metabolites not 
included in the master peak list were not found. In this study, a multinormal distribution was 
applied to describe the distribution of the “good” batches in the latent space of the PCA model. 
In case of more complex distributions, it is possible to apply the kernel density estimation 
method to evaluate the distribution of the training set samples in the latent space and the 
distribution of the residuals. The proposed method, based on the GS and on the master peak 
list used for peak matching, depends on the sample selected as GS. However, since the 
collected samples correspond to the same product, in principle it is possible to replace the old 
GS with a new one having approximately the same number of peaks of the master peak list. 
Therefore, if one want to re-use all the samples collected in the past, the master peak list 
should be updated by excluding the peaks not found in the new GS, while data normalization 
can be recalculated based on the new GS, once the new GS is run together the old GS.  
In a routine quality control metabolomics analysis, the following workflow can be used as 
Standard Operating Procedure (SOP) for monitoring batches quality: acquisition of the new 
sample in triplicate with related GS and blank samples randomizing the experimental runs; 
matching of the replicates to the master peak list; normalize the data; calculation of the median 
of the replicates; projection of the sample on the control charts; evaluation of the compliance 
on the basis of the control charts (PCA scores, DModX+); update the control charts with the 
compliant samples. If the sample is not compliant to the “good” quality batches, it is necessary 
to proceed to checkout and only after more insights if the batch meets the quality 
requirements the control charts can be updated. Remarkably, this approach is currently under 
investigation at the Quality Control Department of Aboca S.p.a. as a new, alternative and/or 
complementary method to the traditional quality control process, for monitoring the quality of 
formulated natural complex products. In this regard, since the goal of the proposed approach 
was to define statistically significant criteria to evaluate the batch quality of formulated natural 
products without the need to identify the single metabolites, its main limitation at this stage is 
related to the impossibility to understand and define, within the obtained metabolomic 
fingerprinting comparison, the metabolites that, changing in their quali-quantitative profile, are 
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responsible for the incompliance to the quality requirements. Thus, as a future perspective this 
study will be further integrated with a complementary targeted analysis to recognize those 
metabolites acting as biomarkers for the batch quality and this preliminary investigation will be 
object of the following paragraph of this PhD Thesis. 
 
Materials and methods  
Absolute ethanol 99.8% and pure methanol 99.9% were purchased from Sigma-Aldrich (St. 
Louis, MO). Ultrahigh purified water was prepared in a PURELAB® Ultra water purification 
system (ELGA, UK). Grintuss® adult syrup was produced by Aboca S.p.a. (Sansepolcro, Italy). 
Samples preparation consisted in the solubilisation of 0.5 g of Grintuss® adult syrup in a 100 mL 
glass volumetric flask with ethanol/water (50:50, w/w) in ultrasonic bath (Branson 5800 
Ultrasonic Cleaner) for 20 minutes setting temperature at 35 °C, then make up to the mark at 
room temperature. The solution obtained was then homogenized and, after filtration on 0.45 
μm Millipore cellulose acetate syringe filter, was transferred in a vial and analyzed without 
further dilution. An aliquot of each filtered solution was also stored at -80 °C. FIA-ESI-MS 
analysis was carried out in a HPLC 1100 Series (Agilent Technologies INC., Santa Clara, CA) 
system equipped with a vacuum degasser, a binary pump, a Peltier thermostated autosampler 
at 10 °C and the outcome was analyzed by an Ion Trap Mass Spectrometer SL series equipped 
with an ESI interface (Agilent Technologies INC., Santa Clara, CA). The column was replaced by 
an adapter connecting the capillaries between the injector and the interface and the flow rate 
was 0.2 mL min-1, with an injector volume of 5 µL. The mobile phase consisted of methanol (A) 
and ultrapure water (B) according the following elution: 0-5 min A/B 50:50 (v/v). Before 
injecting a new sample, a system equilibration of 20 minutes was performed, using A/B 50:50 
(v/v) as eluting solvent. The MS parameters were optimized in wide mode, with a width from 
50 to 1,500 m/z. The ion trap mass spectrometer optimized parameters were the following: 
entrance capillary voltage: +4,500 V; end plate offset: -500 V; dry gas flow: 8 L min-1; dry 
temperature: 350 °C; skimmer: -33.1 V; capillary exit: -111.5 V; oct 1 DC: -12.00 V; oct 2 DC:               
-1.70 V; otc RF: 300.0 Vpp; lens 1: 5.5 V; lens 2: 57.2 V; trap drive: 45.2; nebulizer gas pressure: 
20 psi. Multivariate statistical data analysis was performed by SIMCA13 (Umetrics, Umea, 
Sweden) while data pre-treatment was applied by R-functions developed within the platform R 
3.0.2 (R Foundation for Statistical Computing). 
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2.2 Metabolites profiling of Grintuss® syrup by a targeted metabolomics approach 
Advances in phytochemical investigations have always been related to innovations in 
analytical technology. Thanks to the improved performance in terms of pressure limits, extra-
column dispersion and shorter time of analysis with respect to traditional HPLC, UHPLC-based 
analytical platforms have been becoming a standard technique for quali-quantitative plant 
metabolomics studies.86 On the other hand, the high specificity, accuracy and selectivity 
associated with the relatively short time for methods development have thrust MS techniques 
coupled with UHPLC systems into the limelight as valuable tools for quali-quantitative plant 
metabolomics studies. Obviously, the ability to enable simultaneous qualitative and 
quantitative profiling in a single run is highly desirable and, to this aim, UHPLC-MS platforms 
must be assisted by powerful software for data handling. However, despite the unremitting 
advances in terms of mass resolution, mass accuracy, mass range and sensitivity, the 
identification and quantification of metabolites in comprehensive plant metabolomics 
experiments with a single analytical LC-MS platform is still not possible due to impossibility to 
cover the whole chemical space of plant metabolome. As an additional challenge, 
metabolomics studies of formulated natural products in a single analysis imply the detection of 
thousands of components, some of them are unknown or still not commercially available as 
reference standards, within a wide range of chemical structures, molecular masses, dynamic 
concentration range and MS responses. This requires to solve issues related with both the 
chromatographic method and the MS parameters, including the coelution of highly polar 
metabolites at the solvent front, the competition in the use of the energy available for 
ionization at the source of the MS, mutual ion suppression phenomena and matrix effects. 
Thus, many factors need to be considered to set-up a LC-MS platform for natural products 
analysis: sample preparation, which should be as simple as possible with the minimal number 
of steps required; selection of LC-MS instruments; optimization of LC conditions and MS 
parameters for high resolution and sensitivity, as well as exploitation of structure information 
based on fragmentation patterns for the confirmation of known compounds or the 
identification of unknown components.86  
Based on the properties of the phytochemical constituents to be analyzed in a qualitative LC-
MS analysis, the most appropriate ionization mode (positive or negative) should be chosen 
accordingly. In this regard, the elucidation of the fragmentation patterns based on MSn or 
MS/MS spectra in LC-MS is still far from reach the level of knowledge obtained for GC-MS over 
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the years. Thus, LC-MS-based qualitative plant metabolomics studies require the construction 
of standard reference compounds databases useful to understand the relationship between 
structural features and fragmentation patterns, allowing the matching of target metabolites in 
natural complex products.86  
On the other hand, quantitative analysis of phytochemical constituents are currently 
performed using MS instruments capable of MS/MS ion transition like QqQ or Q-Trap. The 
combination of the specific parent mass and the unique fragment ion is used to selectively 
monitor the compound of interest, which highly improves the sensitivity and specificity of 
analysis. Generally, the limit of quantification using LC-MS/MS is between 0.01 and 100 ng mL-1. 
However, for the quantitative analysis of whole formulated natural products, matrix effects are 
likely to occur, thus resulting in a significant reduction of the accuracy and precision of the 
measurement using LC-MS. In this regard, the sample preparation, as well as the optimization 
of LC and MS parameters, are crucial to solve ion suppression phenomena and to reach an 
acceptable compromise between resolution and analysis time.86  
The last years have witnessed a marked growth in the applications of UHPLC-MS for natural 
products analysis both in companies and academia. Encouraged by the promising results 
achieved towards the batch quality evaluation of whole formulated natural products and with 
the aim to provide a deeper knowledge of their quali-quantitative composition to comply the 
forthcoming recast regulation on medical devices (Regulation EU 2017/745), the second part of 
this PhD Thesis was focused on the development of a targeted metabolomics approach by 
means of liquid chromatography-high resolution mass spectrometry (LC-HRMS) technique for 
the metabolites profiling of whole formulated natural products.  
In particular, choosing again Grintuss® syrup as the model of natural complex matrices, we 
have attempted to go beyond the traditional analytical studies by developing an unique UHPLC-
ESI-Q-TOF method for its quali-quantitative metabolic profiling by avoiding any prior sample 
manipulation, controlling the matrix effect by simple dilution and using only one internal 
standard for normalization. The project has involved firstly the construction of an in-house 
database obtained by acquiring the MS and MS/MS spectra of high purity standard reference 
compounds purchased from different suppliers. The next step has been represented by the 
acquisition of the mass spectra of the precursor and fragment ions of the detected metabolites 
in the samples under investigation with the same LC method adopted for the standard 
compounds, followed by the matching assessment between the fragment ions mass spectra of 
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the detected metabolites in the sample and the in-house fragment database. Finally, 
quantitative analysis of the recognized metabolites in the product was performed (Figure 12).  
 
 
Figure 12 ̶ Workflow adopted for the quali-quantitative metabolites profiling of natural complex 
products. 
 
 
In-house database of high purity standard reference compounds 
Multi-mode or simultaneous ion sources, as well as pulsed and parallel use of different 
ionization techniques are generally required to obtain detailed structural information from the 
wide variety of metabolites contained in complex natural matrices (Figure 13).87  
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Figure 13   ̶   Coverage of molecule classes with different ionization methods.88 
 
In this regard, free chemical databases based on EI techniques are useful for mass spectral 
library matching since the hard ionization energy used affords highly reproducible 
fragmentations patterns. On the other hand, free chemical databases based on electrospray 
tandem mass spectra and other soft ionization techniques are more detailed but less 
reproducible since the resulting fragmentation patterns depend on a large number of factors, 
including the type of the instrument, ion source designs, ion source potentials, mobile phase 
effects, and many others which are not properly understood. 
Thus, initial efforts have been devoted to build an in-house library containing the 
fragmentation patterns of reference compounds of interest. In pursuing this aim, almost 1,000 
high-purity reference standards, belonging to different chemical classes, including phenols, 
terpens, organic acids, sulphur and nitrogen compounds and water-soluble vitamins, were 
purchased from Extrasynthese, Sigma-Aldrich, Phytolab and Chromadex. Accordingly, with the 
aim to set-up a general and unique UHPLC-ESI-Q-TOF protocol endowed with a broad 
applicability on the diverse classes of chemical components belonging to different complex 
natural matrices, a suitable LC-MS method for the acquisition of standard compounds and for 
the samples analysis was developed. The instrumental platform used was an UHPLC coupled to 
a hybrid quadrupole time-of-flight (Q-TOF) mass spectrometer (Figure 14). For the 
chromatographic separation, the last generation C18 Cortecs® (Waters) was selected as highly 
efficient column. Characterized by a non-porous solid-core of silica in the center of the particle 
that is surrounded by an outer layer of porous silica, where the chromatographic separation 
takes place, this column is designed to give maximum efficiency, with the narrowest peak 
widths and highest resolution.89  
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Figure 14  ̶  Schematic representation of a hybrid quadrupole time-of-flight (Q-TOF) used for this study 
(adapted from Agilent Technologies). 
 
 
The best compromise in terms of separation of the main constituents, method length and 
peaks resolution was obtained using aqueous HCO2H (0.1%, v/v) and HCO2H (0.1%, v/v in 
MeOH) as mobile phase with a gradient elution, from 1% to 99% of the organic phase in 24 
minutes. So far, almost 800 standard reference compounds solutions were acquired at 
concentrations ranging from 100 to 500 ppb. In this regard, the acquisition in both ESI+ and ESI- 
mode by data dependent mode (Auto MS/MS modality in Agilent Technologies) allowed the 
isolation of the pseudo-molecular ion and its subsequent fragmentation to obtain a 
characteristic pattern of product ions for each reference standard. On the other hand, the use 
of three collision energy values (20, 30 and 40 eV) was crucial to ensure the dissociation of all 
the reference compounds allowing to obtain more detailed fragmentation patterns. The 
information acquired for each standard compound (molecular formula, monoisotopic mass 
value, structure, retention time value and MS/MS spectra) were collected in the in-house 
database using Agilent MassHunter Personal Compound Database and Library (PCDL) software 
(Figure 15). 
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Figure 15  ̶  Screenshot of the in-house database interface showing molecular formula, monoisotopic 
mass value, structure, retention time value (A) and MS/MS spectra acquired at 20, 30 and 40 eV (B) of a 
selected reference standard. 
 
Calibration curves for the reference standard compounds 
After having collected the retention time and the fragmentation pattern of each standard 
compound, the second part of the work was dedicated at the construction of calibration curves 
for the subsequent quantitative analysis. In this regard, given the high number of reference 
standard compounds acquired for the in-house library, which is still under continuous 
implementation, the building of a calibration curve for each compound would be extremely 
time-consuming, expensive and low throughput. Thus, 6 stock solutions were prepared by 
mixing 50-150 standard reference compounds for each mix stock solution. Moreover, in order 
to simplify as much as possible the process by preventing incorrect detections, compounds 
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endowed with identical monoisotopic mass and similar retention time were dissolved in 
different mix stock solutions, while no further consideration concerning the potential mutual 
chemical reactivity among the components dissolved in the same stock solution has been 
made. As well known, a quantitative determination requires the acquisition of reference 
standard compounds dissolved in the same matrix of the sample to be analyzed. In other 
words, a typical quantitative determination is matrix-dependent and requires the construction 
of a different calibration curve for each matrix under investigation. In this regard, the 
unavailability of certified blank matrices for natural complex products as well as the need to 
develop a general targeted metabolomics approach applicable to different natural complex 
matrices, led us to built the calibration curves in pure solvent and therefore to consider a semi-
quantitative rather than a properly called quantitative approach. Thus, each mix stock solution 
was prepared in H2O/MeOH (50:50, v/v) and opportunely diluted to obtain from 5 to 10 
calibration standards. Moreover, an aliquot of sulfadimethoxine-d6 stock solution (5 ppm, 20 L 
per mL of calibration standard), selected as the internal standard, was added to each mix 
calibration standard. All these operations were conducted in a high-throughput fashion by 
using Agilent Sample Prep WorkBench (Figure 16).  
 
 
Figure 16  ̶  Agilent Sample Prep WorkBench. 
 
The mix calibration standards were acquired in triplicate using the same LC method 
previously adopted for building the in-house library but with a different MS modality. In 
particular, data were acquired both in ESI+ and ESI- mode with a “low channel” and “high 
channel” using Collision Energy (All Ions mode in Agilent Technologies). In other words, the 
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acquisition of each mix calibration standard was performed using two simultaneous scanning 
functions: the first acquisition was performed at low energy in order to extrapolate the exact 
mass precursor ion spectra, while the second was acquired at higher energy to provide the 
exact mass of the fragment ions. Then, for each mix stock solution, the data file of a selected 
mix calibration standard (for convention the most concentrated point of the curve was chosen) 
was loaded into MassHunter Qualitative analysis software and the algorithm Find-by-Formula 
was run on the low channel against the in-house MS/MS library. Thus, the algorithm allowed 
the matching between possible precursor formulas and their product ions found in the library. 
Using the list of product ions, the software extrapolated extracted ion chromatograms (EICs) 
from the high channel and aligned them with an EIC of the precursor. A coelution score was 
calculated and compounds which passed the user-set threshold were retained. Then, the 
compounds were exported as a Compound Export Format (.CEF) file and loaded into the 
MassHunter Quantitative software. The list of precursors and product ions with their retention 
times was used to create the quantitative method. Following this approach, linear calibration 
curves were generated over the range 10-2,000 ppb with values for the correlation coefficient 
R2 ≥0.98, according to the Agilent All Ions MS/MS Targeted Screening Workflow (Figure 17). 
 
 
 
Figure 17  ̶  All Ions MS/MS targeted screening workflow (adapted from Agilent Technologies). 
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Quali-quantitative metabolic profiling of Grintuss® pediatric syrup  
The targeted metabolomics platform thus developed was applied for the quali-quantitative 
metabolic profiling of Grintuss® pediatric syrup. With this aim, three samples, for each of the 
four batches of Grintuss® pediatric syrup under investigation, were prepared by dissolving 0.5 g 
of the syrup in 50 mL of H2O/MeOH (50:50, v/v) (10 mg mL
-1). The samples were then filtered 
and acquired both in negative and positive mode at three different concentrations (as it is, 1:10 
and 1:50 in H2O/MeOH, 50:50, v/v) in presence of sulfadimethoxine-d
6 as the internal standard 
(20 L per mL of solution; 5 ppm concentration), using the same LC-MS method adopted for the 
calibration curves. Moreover, one calibration standard for each mix stock solution was acquired 
together with the samples and the relative accuracy on the curve previously obtained was 
calculated. As an example, the total ion chromatograms (TICs) in ESI- and ESI+ relative to batch 
n° 2 of Grintuss® pediatric syrup for the sample injected at 10 mg mL-1 are shown in Figure 18.  
 
 
Figure 18  ̶  Total ion chromatograms (TICs) in ESI- (A) and ESI+ (B) relative to batch n° 2 of Grintuss® 
pediatric syrup for the sample injected at 10 mg mL-1. 
 
The qualitative analysis was performed according to the previously described workflow. The 
data files for the different batches of Grintuss® pediatric syrup acquired as it is was loaded into 
MassHunter Qualitative analysis software and the algorithm Find-by-Formula was run to 
evaluate the presence of specified compounds by searching the chromatogram for each of the 
formula selected in the Formula Source. In particular, in this work the in-house database 
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natural_compound.cdb was selected as source of formula (Figure 19A). The match tolerance 
was set as ±10 ppm for masses and ±0.7 minutes for retention times and, concerning the 
scoring, the contribution (%) to overall score was set as 100 for mass score, 60 for isotope 
abundance score, 50 for isotope spacing score and 100 for retention time score. Moreover, the 
option Confirm with fragment ions in Fragment Confirmation tab was marked, thus the 
software selects known fragment ions from the MS/MS spectra, qualifies those fragment ions 
that can be seen with appropriate signal-to-noise, and then qualifies those fragment ions that 
have the same elution profile as the precursor ion (Figure 19B). 
 
 
Figure 19  ̶  Screenshot of the Find-by-Formula algorithm of MassHunter Qualitative analysis software 
showing the formula source tab (A) and the fragment confirmation tab (B) containing the fragment ion 
EIC qualification settings (retention time difference, signal to noise ratio and coelution score). 
 
 
The identified compounds of the negative acquisition after the Find-by-Formula are shown in 
Table 6, while compounds qualified in the positive acquisition are shown in Table 7.  
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Table 6  ̶  Qualified compounds of Grintuss® pediatric syrup in ESI-. 
RT (min) m/z Formula Compound name Score Flags (Tgt) 
0.781 193.0370 C6H10O7 
D-Glucuronic acid
a
 83.17 
Qualified (multiple IDs) 
Galacturonic acid
a
 83.11 
0.849 191.0567 C7H12O6 (-)-Quinic acid 87.62 Qualified 
1.255 191.0206 C6H8O7 Citric acid 94.67 Qualified
b
 
1.458 225.0623 C6H12O6 Fructose
a
 79.07 Qualified 
1.594 187.0255 C6H6O4 Kojic acid
a
 86.82 Qualified 
2.338 407.1199 C15H22O10 Catalpol 91.74 Qualified 
2.846 391.1248 C15H22O9 Aucubin 98.42 Qualified 
3.049 153.0202 C7H6O4 
-Resorcylic acid 91.60 
Qualified (multiple IDs) 
Protocatechuic acid 90.91 
3.185 353.0893 C16H18O9 Neochlorogenic acid
a
 87.09 Qualified 
3.354 339.0715 C15H16O9 Aesculin (Vitamin C2) 74.16 Qualified (low score) 
3.455 375.1293 C16H24O10 Loganic acid 80.59 Qualified
b
 
3.658 353.0879 C16H18O9 
Neochlorogenic acid 93.91 
Qualified (multiple IDs) Chlorogenic acid 91.87 
Cryptochlorogenic acid 89.12 
3.692 459.1146 C18H22O11 Asperuloside
a
 95.24 Qualified 
3.895 177.0204 C9H6O4 Esculetin 55.43 Qualified (low score)
b
 
4.572 639.1547 C27H30O15 
Vicenin-2
a
 69.76 
Qualified (multiple IDs) 
Saponarin 67.82 
5.013 479.0834 C21H20O13 Quercetagetin 7-O-glucoside 78.03 Qualified 
5.656 639.1923 C29H36O16 Plantamajoside 86.66 Qualified 
6.333 639.1896 C29H36O16 Plantamajoside 60.62 Qualified (low score) 
6.333 623.1983 C29H36O15 Verbascoside 97.30 Qualified 
6.468 447.0931 C21H20O11 
Luteolin 7-O-beta- 
D-glucoside 
92.74 
Qualified (multiple IDs) 
Maritimein 92.27 
Homoorientin 80.15 
6.367 515.1192 C25H24O12 
3,4-Dicaffeoylquinic acid 92.39 
Qualified (multiple IDs) 
3,5-Dicaffeoylquinic acid 88.71 
6.773 137.0244 C7H6O3 Salicylic acid 88.32 Qualified 
6.942 816.2622 C35H46O19 Poliumoside
c
 51.28 Qualified (low score) 
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a
 Calibration curve not available. 
b
 Peak not well resolved or shifted. 
c
 Structural isomer. 
 
 
 
 
 
 
 
7.145 623.1972 C29H36O15 Verbascoside
c
  79.39 Qualified 
7.518 445.0777 C21H18O11 Apigenin 7-O-glucuronide 97.63 Qualified 
7.585 515.1192 C25H24O12 4,5-Dicaffeoylquinic acid 95.59 Qualified 
8.127 187.0975 C9H16O4 Azelaic acid 71.88 Qualified (low score) 
8.262 623.1607 C28H32O16 Isorhamnetin 3-O-rutinoside 74.95 Qualified (low score)
b
 
8.905 263.1272 C15H20O4 (+/-)-Abscisic acid
a
 69.40 Qualified (low score) 
9.955 271.0613 C15H12O5 
Naringenin 88.05 
Qualified (multiple IDs) 
Pinobanksin 83.12 
10.158 285.0404 C15H10O6 Luteolin 80.17 Qualified 
10.496 637.1868 C28H32O14 Linarin
a
 62.41 Qualified (low score) 
10.564 315.0516 C16H12O7 6-Methoxyluteolin (Nepetin) 72.33 Qualified (low score) 
11.546 269.0456 C15H10O5 
Apigenin 95.86 
Qualified (multiple IDs) 
Genistein 84.05 
11.884 299.0559 C16H12O6 Hispidulin
a
 95.31 Qualified 
12.629 329.0672 C17H14O7 
Quercetin  
3,4'-dimethyl ether 
87.01 Qualified 
13.746 343.0820 C18H16O7 Eupatorin
a
 91.94 Qualified 
14.423 253.0507 C15H10O4 
7-Hydroxyflavonol 78.68 
Qualified (multiple IDs) 3,6-Dihydroxyflavone 67.76 
Chrysin 67.22 
15.032 283.0610 C16H12O5 
Acacetin
a
 88.14 
Qualified (multiple IDs) 
Genkwanin
a
 81.75 
17.063 401.1608 C22H26O7 Arzanol 93.69 Qualified 
18.688 319.2279 C20H32O3 Grindelic acid 95.65 Qualified 
19.331 455.3533 C30H48O3 
Bacosine
a
 87.23 
Qualified (multiple IDs) 
Oleanolic acid 85.21 
20.279 283.2642 C18H36O2 Stearic acid
a
 93.35 Qualified 
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Table 7  ̶  Qualified compounds of Grintuss® pediatric syrup in ESI+. 
RT (min) m/z Formula Compound name Score Flags (Tgt) 
0.745 104.1070 C5H14NO Choline chloride 99.51 Qualified (no H-adduct) 
0.779 118.0867 C5H12NO2 Betaine
a
 98.59 Qualified (no H-adduct) 
1.050 136.0617 C5H5N5 Adenine
a
 74.02 Qualified (low score) 
2.336 385.1060 C15H22O10 Catalpol 57.33 Qualified (low score) 
2.844 369.1156 C15H22O9 Aucubin 97.89 Qualified 
3.656 355.1028 C16H18O9 
Neochlorogenic acid
a
 93.44 
Qualified (multiple IDs) Chlorogenic acid 91.25 
Cryptochlorogenic acid 88.49 
3.690 437.1058 C18H22O11 Asperuloside
a
 91.20 Qualified 
3.758 395.1330 C17H24O9 Eleutheroside B
a
 77.12 Qualified 
6.229 633.1454 C27H30O16 Luteolin 3',7-di-O-glucoside 70.47 Qualified (low score)
b
 
6.331 479.1550 C23H26O11 Calceolarioside B 73.87 Qualified (low score)
b
 
6.364 539.1156 C25H24O12 
3,4-Dicaffeoylquinic acid 91.76 
Qualified (multiple IDs) 
3,5-Dicaffeoylquinic acid 88.08 
6.364 463.0872 C21H18O12 Luteolin 7-O-glucuronide 81.21 Qualified 
6.906 793.2535 C35H46O19 Poliumoside 62.37 Qualified (low score) 
7.143 163.0387 C9H6O3 3-Hydroxycoumarin 79.10 Qualified
b
 
7.143 479.1546 C23H26O11 Calceolarioside B 83.79 Qualified 
7.515 447.0928 C21H18O11 Apigenin 7-O-glucuronide 96.29 Qualified 
7.786 478.1062 C22H22O12 
Nepetin 7-glucoside 79.57 Qualified (multiple IDs, 
no H-adduct) Isorhamnetin 3-O-glucoside
a
 66.03 
8.903 287.1257 C15H20O4 (+/-)-Abscisic acid
a
 74.09 Qualified (low score) 
9.513 303.0508 C15H10O7 
Herbacetin
a
 86.17 
Qualified (multiple IDs) Tricetin 82.74 
Quercetin
a
 71.24 
10.156 287.0548 C15H10O6 Luteolin 75.18 Qualified 
10.257 229.0474 C11H10O4 Citropten 76.76 Qualified 
10.528 593.1880 C28H32O14 Linarin
a
 62.06 Qualified (low score) 
10.562 317.0667 C16H12O7 6-Methoxyluteolin (Nepetin) 85.52 Qualified 
11.577 271.0604 C15H10O5 
Apigenin 82.07 
Qualified (multiple IDs) 
Genistein 68.39 
11.882 301.0713 C16H12O6 Hispidulin
a
 90.18 Qualified 
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12.627 331.0804 C17H14O7 Quercetin 3,4'-dimethyl ether 78.06 Qualified 
13.744 345.0974 C18H16O7 Eupatorin
a
 87.25 Qualified 
13.812 257.0811 C15H12O4 Pinocembrin
a
 63.10 Qualified (low score) 
14.590 343.1177 C19H18O6 
Scutellarein tetramethyl ether 90.68 
Qualified (multiple IDs) 3',4',7,8-Tetramethoxyflavone 85.96 
Luteolin tetramethylether 77.58 
14.658 425.1222 C21H22O8 
3',4',5,5',6,7-
Hexamethoxyflavone 
86.77 
Qualified (multiple IDs) 
Nobiletin 80.36 
15.403 849.4237 C42H66O16 
Bayogenin 3-O-beta-D-
glucuronopyranoside-28-O-
beta-D-glucopyranosyl ester
a
 
75.20 Qualified 
15.470 373.1285 C20H20O7 Tangeretin 84.01 Qualified 
17.129 425.1574 C22H26O7 Arzanol 95.45 Qualified 
18.585 351.1571 C20H24O4 
5-Geranyloxy-7-
methoxycoumarin 
77.58 Qualified 
a
 Calibration curve not available. 
b
 Peak not well resolved or shifted. 
 
The outcome of the algorithm is represented by a compound list table described by different 
columns: the retention time assigned to the compound, the mass-to-charge ratio of the 
precursor or largest evidence ion for this compound, the empirical formula, the name of the 
compound, the overall score of the identification results and the Flags (Tgt). These flags explain 
the reasons why there is not a match for this target or the reasons for which the match may be 
incorrect (Figure 20). 
 
 
Figure 20 ̶  Screenshot of the Result Filters tab of the Find-by-Formula algorithm of MassHunter 
qualitative analysis software.  
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In particular, compounds shown in Tables 6 and 7 represent only the qualified entities with 
at least one fragment ion of the in-house MS/MS library. Moreover, the flag Multiple IDs 
indicates that a precursor formula found matched more than a compound of the in-house 
database. 
Within the qualified compounds, 21 metabolites have been quantified so far and the results, 
expressed as % w/w (mean ± standard deviation) for the four batches of Grintuss® pediatric 
syrup prepared in triplicate, are shown in Figure 21 and Table 8, while the relative EICs of the 
quantified compounds in negative and positive mode are reported in Figure 22. 
 
 
Figure 21  ̶  Quantified metabolites in four batches of Grintuss® pediatric syrup. 
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Table 8  ̶  Quantified compounds of Grintuss® pediatric syrup. 
Compound 
MS  
mode 
Batch 1 Batch 2 Batch 3 Batch 4 
Mean (% w/w) ± SD Mean (% w/w) ± SD Mean (% w/w) ± SD Mean (% w/w) ± SD 
5-Geranyloxy-7-
methoxycoumarin 
ESI+ 0.000080±0.000004 0.000119±0.000005 0.00011±0.00001 0.000105±0.000008 
Arzanol ESI+ 0.00032±0.00001 0.00027±0.00001 0.000246±0.000002 0.00061±0.00007 
Azelaic acid ESI- 0.0004±0.0001 0.00020±0.00004 0.00019±0.00002 0.0003±0.0001 
Salicylic acid ESI- 0.00054±0.00005 0.00031±0.00008 0.00033±0.00009 0.00025±0.00004 
Quercetagetin  
7-O-glucoside 
ESI- 0.0007±0.0002 0.00045±0.00005 0.00048±0.00004 0.00046±0.00008 
Luteolin ESI- 0.00084±0.00004 0.00058±0.00001 0.00052±0.00003 0.00042±0.00001 
(-)-Quinic acid ESI- 0.0011±0.0002 0.0011±0.0002 0.0009±0.0001 0.00107±0.00008 
Apigenin 
7-O-glucuronide 
ESI- 0.0014±0.0002 0.0013±0.0001 0.00115±0.00005 0.00100±0.00004 
Protocatechuic acid ESI- 0.0015±0.0001 0.0010±0.0002 0.0009±0.0002 0.00087±0.00006 
Cryptochlorogenic 
acid 
ESI- 0.00151±0.00001 0.00157±0.00002 0.00151±0.00006 0.00149±0.00003 
Poliumoside isomer ESI- 0.0018±0.0002 0.00047±0.00004 0.00047±0.00003 0.00039±0.00004 
Luteolin 
7-O-glucuronide 
ESI+ 0.0021±0.0001 0.0023±0.0002 0.0022±0.0002 0.0021±0.0002 
4,5-Dicaffeoylquinic 
acid 
ESI- 0.00257±0.00007 0.0029±0.0002 0.00288±0.00009 0.00243±0.00007 
Choline chloride ESI+ 0.00364±0.00008 0.0043±0.0002 0.0040±0.0001 0.0036±0.0001 
Chlorogenic acid ESI- 0.0039±0.0002 0.0061±0.0005 0.0068±0.0005 0.0067±0.0008 
3,4- and 3,5-
dicaffeoylquinic acid 
ESI- 0.0042±0.0003 0.0034±0.0002 0.0033±0.0001 0.0028±0.0002 
Plantamajoside ESI- 0.0050±0.0004 0.00140±0.00002 0.00128±0.00008 0.00106±0.00007 
Catalpol ESI- 0.0062±0.0008 0.0042±0.0005 0.0034±0.0003 0.0032±0.0002 
Grindelic acid ESI- 0.0085±0.0004 0.0035±0.0003 0.0044±0.0004 0.0045±0.0004 
Aucubin ESI- 0.010±0.001 0.0086±0.0002 0.0086±0.0003 0.0086±0.0003 
Verbascoside ESI- 0.081±0.006 0.029±0.002 0.026±0.006 0.0236±0.0009 
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Figure 22  ̶  Extracted ion chromatograms (EICs) in ESI- (A) and ESI+ (B) of the quantified compounds in 
Grintuss® pediatric syrup. 
 
 
 
 In Tables 9 and 10 are reported the parameters for the calibration curve obtained for each 
quantified compound and the quantifier/qualifier ions used for the quantification, respectively. 
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Table 9  ̶  Parameters for the calibration curve obtained for each quantified compound. 
a
 The reported parameters refer to the calibration curve obtained for poliumoside. 
b
 The reported parameters 
refer to the calibration curve obtained for 3,4-dicaffeoylquinic acid. 
 
 
 
Compound Slope Intercept R
2
 Accuracy (%) 
5-Geranyloxy-7-
methoxycoumarin 
0.006369 -0.026075 0.993 80.5 
Arzanol 0.006726 -0.019887 0.997 70.2 
Azelaic acid 0.016553 -0.005007 0.999 50.0 
Salicylic acid 0.014720 -0.099543 0.995 122.7 
Quercetagetin 7-O-glucoside 0.003952 -0.091069 0.985 37.5 
Luteolin 0.016199 -0.262530 0.989 98.2 
(-)-Quinic acid 0.006094 -0.206513 0.975 250.3 
Apigenin 7-O-glucuronide 0.004105 -0.114936 0.987 152.7 
Protocatechuic acid 0.009157 -0.279345 0.997 170.9 
Cryptochlorogenic acid 0.008126 -0.348388 0.978 135.0 
Poliumoside isomer
a
 0.004289 -0.024018 0.996 54.3 
Luteolin 7-O-glucuronide 0.000948 +0.046902 0.997 81.9 
4,5-Dicaffeoylquinic acid 0.002673 -0.020450 0.994 137.3 
Choline chloride 0.004900 +0.172359 0.987 141.3 
Chlorogenic acid 0.002489 -0.009334 0.997 174.2 
3,4- and 3,5-Dicaffeoylquinic 
acid
b
 
0.006219 -0.155355 0.994 53.0 
Plantamajoside 0.005780 -0.143145 0.982 49.3 
Catalpol 0.005843 -0.061174 0.985 67.7 
Grindelic acid 0.000596 -0.015451 0.986 120.2 
Aucubin 0.009797 -0.343048 0.991 73.7 
Verbascoside 0.002859 -0.002965 0.995 151.4 
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 Table 10  ̶  Quantifier and qualifier ions used for the quantification. 
a
 The reported information refers to poliumoside. 
 
 In conclusion, this study allowed the identification of almost hundred metabolites contained 
in Grintuss® pediatric syrup. Within the qualified compounds, 21 metabolites have been 
quantified so far allowing to reach 0.07-0.14% (w/w) of the overall composition of Grintuss® 
pediatric syrup. In particular, the quantified metabolites belong to the following classes: 
flavonoids (quercetagetin 7-O-glucoside, apigenin 7-O-glucuronide, luteolin, luteolin 7-O-
Compound 
Quantifier Ion 
Species 
Quantifier (m/z) Qualifier (m/z) 
5-Geranyloxy-7-
methoxycoumarin 
[M+H]
+
 329.1747 193.0480 
Arzanol [M+H]
+
 403.1751 
181.0502; 
155.0705 
Azelaic acid [M-H]
-
 187.0976 125.0971 
Salicylic acid [M-H]
-
 137.0244 
93.0346;  
65.0397 
Quercetagetin 7-O-glucoside [M-H]
-
 479.0831 317.0293 
Luteolin [M-H]
-
 285.0405 133.0292 
(-)-Quinic acid [M-H]
-
 191.0561 
85.0295; 
59.0138 
Apigenin 7-O-glucuronide [M-H]
-
 445.0776 269.0447 
Protocatechuic acid [M-H]
-
 153.0193 109.0293 
Cryptochlorogenic acid [M-H]
-
 353.0878 
173.0455;  
191.0558 
Poliumoside isomer
a
 [M-H]
-
 769.2561 161.0238 
Luteolin 7-O-glucuronide [M+H]
+
 463.0871 287.0549 
4,5-Dicaffeoylquinic acid [M-H]
-
 515.1195 
173.0454; 
353.0875 
Choline chloride M+ 104.1070 
60.0807;  
58.0652 
Chlorogenic acid [M-H]
-
 353.0878 
191.0559;  
85.0293 
3,4- and 3,5-Dicaffeoylquinic 
acid 
[M-H]
-
 515.1195 
173.0451;  
179.0342 
Plantamajoside [M-H]
-
 639.1931 477.1611 
Catalpol [M+COOH]
-
 407.1195 
169.0504; 
199.0605 
Grindelic acid [M-H]
-
 319.2279 205.1594 
Aucubin [M+COOH]
-
 391.1246 
165.0541;  
183.0653 
Verbascoside [M-H]
-
 623.1981 461.1650 
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glucuronide); phenylpropanoids (poliumoside, chlorogenic acid, cryptochlorogenic acid, 3,4- 
and 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, 5-geranyloxy-7-methoxycoumarin); 
phenethanoids (verbascoside, plantamajoside); salicylates (salicylic acid); simple phenols 
(arzanol); acid phenols (protocatechuic acid); iridoides (aucubin, catalpol); diterpenes (grindelic 
acid); carboxylic acids ((-)-quinic acid, azelaic acid) and hydro-soluble vitamins (choline).  
 As previously discussed, this work is still currently ongoing with a continuous 
implementation of the in-house library of standard reference compounds as well as by building 
of additional calibration curves required for the quantification of the remaining qualified 
metabolites. The quali-quantitative profiling obtained by applying this targeted metabolomics 
LC-MS-based approach was then combined with the results deriving from others analytical 
facilities for the analysis of additional compounds as polysaccharides and minerals allowing to 
reach so far up to 99.9% of the overall composition of Grintuss® pediatric syrup (Table 11).  
 
Table 11   ̶  Overall composition of Grintuss® pediatric syrup determined so far. 
  
 
Class of compounds Mean % (w/w)  Analytical technique 
Phenols 0.0002047 GC-MS 
Monoterpenes 0.0520554 GC-MS 
Sesquiterpenes 0.0000500 GC-MS 
Apocarotenids 0.0000340 GC-MS 
Aromatic and aliphatic alcohols 0.0033180 GC-MS 
Aromatic aldehydes, acids, esters 
and ketones 
0.0026370 GC-MS 
Esters 0.0000630 GC-MS 
Mono- and di-saccharides 71.050000 GC-FID 
Sterols 0.0022290 GC-FID 
Threecarboxylic acids 0.1230000 HPLC-DAD 
Polysaccharides 0.5487500 HPLC-RID 
Fructoligosaccharides 0.2000000 Gravimetric  
Minerals 0.0854530 ICP-MS 
Proteins and aminoacids 0.0263730 HPLC-Fluorescent 
Water 27.785000 Karl-Fisher 
This study (mean) 0.0866237 UHPLC-MS 
TOTAL 99.9657908% 
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 Although this work is primarily focused on the quali-quantitative profiling of Grintuss® syrup, 
the general approach and workflow described possess a more widely scope, thus opening the 
way for the metabolomics investigation of others formulated natural complex products and 
crude plant extracts according to the requirements recently approved by the European 
Parliament in the field of medical devices. 
 
Materials and methods  
All solvents were of high purity analytical grade and were used without further purification. 
ULC/MS grade absolute methanol was purchased from Biosolve (Dieuze, France). Ultrahigh 
purified water was prepared in a PURELAB® Ultra water purification system (ELGA, UK). Formic 
acid 98%-100% for LC-MS LiChropur® and dimethyl sulfoxide ≥99% were purchased from Sigma-
Aldrich (St. Louis, MO). The high-purity reference standards, used both for the construction of 
the in-house database and for the construction of the calibration curves, were purchased from 
Extrasynthese (Genay, France), Sigma-Aldrich (St. Louis, MO), PhytoLab GmbH & Co. KG 
(Vestenbergsgreuth, Germany) and ChromaDex (Irvine, CA). High-purity reference standards 
stock solutions were prepared in methanol, water/methanol (80:20, v/v) or methanol/dimethyl 
sulfoxide (80:20, v/v) at 500 ppm. The working solutions were prepared by diluting appropriate 
volumes of the stock solutions with water/methanol (50:50, v/v). Internal standard 
sulfadimethoxine-d6 was purchased from Sigma-Aldrich (St. Louis, MO). Internal standard stock 
solution was prepared in methanol at 5 ppm. All the stock solutions were stored in glass vials at 
-80 °C. Grintuss® pediatric syrup was produced by Aboca S.p.a. (Sansepolcro, Italy). Samples 
preparation consisted in the solubilisation of 0.5 g of Grintuss® pediatric syrup in a 50 mL glass 
volumetric flask with water/methanol (50:50, v/v) in ultrasonic bath (Branson 5800 Ultrasonic 
Cleaner) for 10 minutes setting temperature at 35 °C, then make up to the mark at room 
temperature. The solution obtained was then homogenized and, after filtration on 0.2 μm 
Millipore cellulose acetate syringe filter, was transferred in a vial and analyzed at different 
concentrations. The instrumental platform used consisted of an UHPLC series 1290 coupled to a 
hybrid quadrupole time-of-flight (Q-TOF) mass spectrometer series 6545 (Agilent Technologies, 
Santa Clara, CA). The UHPLC was endowed with a binary pump, a multisampler, a multicolumn 
thermostat, an isocratic pump and a solvent cabinet. The multisampler was maintained at 15 
°C. The analytical column was a Cortecs® C18 (100 x 2.1 mm, 1.6 µm) protected by a Cortecs® 
UPLC® C18 VanGuard™ pre-column (5 x 2.1 mm, 1.6 µm) both supplied by Waters (Milford, MA) 
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and thermostated at 40 °C. The analyses were performed in elution gradient using aqueous 
HCO2H (0.1%, v/v) as mobile phase A and HCO2H (0.1%, v/v in MeOH) as mobile phase B 
according to the following gradient table (Table 12), with a flow rate of 0.3 mL min-1 and an 
injector volume of 3 µL.  
 
Table 12    ̶ Elution gradient. 
 
 
 
 
 
 
 
 
 
The UHPLC system was coupled to a Q-TOF mass spectrometer endowed with a Dual AJS ESI 
source operating in negative and positive ionization modes with a scan range from 50 m/z to 
1,700 m/z. The optimized instrument parameters are reported in Table 13. 
 
Table 13    ̶ MS parameters. 
 
 
 
 
 
 
 
 
 
 
Time (min) A% B% 
0.0 99 1 
1.0 99 1 
2.0 75 25 
10.0 50 50 
11.0 50 50 
15.0 25 75 
17.0 15 85 
19.0 1 99 
19.5 1 99 
21.0 99 1 
24.0 99 1 
Instrumental parameters ESI- ESI+ 
Gas temperature (°C) 325 325 
Gas flow (L min
-1
) 11 11 
Nebulizer (psig) 35 35 
Sheat gas temperature (°C) 350 350 
Sheat gas flow (L min
-1
) 12 12 
VCap 3,500 3,500 
Nozzle voltage (V) 0 1,000 
Fragmentor 100 100 
Skimmer 65 65 
Octopole RF Peak 750 750 
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The construction of the in-house database was performed by acquiring each analytical 
standard reference compound in data dependent mode (Auto MS/MS, Agilent Technologies) 
using three different collision energy values (20, 30 and 40 eV) by N2. While the acquisition of 
the calibration curves and the acquisition of the sample under investigation was performed in 
All Ions mode using simultaneously four acquisition collision energy values (0, 20, 30 and 40 
eV). In both the acquisition methods, a reference mass solution containing purine and 
hexakis(1H, 1H, 3H-tetrafluoropropoxy)phosphazine was direct injected to the ESI source by the 
isocratic pump and ionized together with the sample solution for mass correction allowing to 
get accurate mass time-of-flight data. MassHunter software version B.07 (Agilent Technologies, 
Santa Clara, CA) was used for data acquisition and processing. 
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3. Concluding Remarks and Future Perspectives 
 
 
 
 
 
Crude plant extracts and natural products deriving from them have been used since ancient 
in folk medicine for treating a broad range of human diseases and represent still today a 
priceless source of new therapeutically remedies. However, the high complexity, diversity and 
variability of formulated natural products in terms of composition makes a challenging task the 
guarantee of their quality, efficacy and safety requirements. In this regard, the current year has 
represented a breaking point in the regulation of medical devices, included those that derive 
from medicinal plant extracts and natural products, due to the recent approval of the EU 
regulation 2017/745 which will force the manufactures to clearly investigate the overall quali-
qualitative composition of the device. In view of this stricter standardization of plant-based 
medical devices, an intense research towards advanced technologies and robust analytical 
protocols is required both for evaluating the composition and for reaching the required quality 
standards.  
Based on these considerations and as a continuation of the phytochemical research activity 
in Aboca S.p.a., this PhD Thesis focuses on the application of targeted and untargeted mass 
spectrometry-based analytical platforms for the metabolomics investigation of formulated 
natural complex products. In pursuing this aim, Grintuss® syrup, a medical device used for 
treating cough and based on honey and functional vegetable substances from Grindelia 
robusta, Plantago lanceolata and Helychrisum italicum, was selected as a model of complex 
formulated natural products to set-up two complementary metabolomics approaches.  
The first approach was based on an untargeted fingerprinting for monitoring the batch-
quality of Grintuss® adult syrup by electrospray ionization mass spectrometry flow injection 
analysis (FIA-ESI-MS). The workflow used has involved the preliminary sample preparation 
followed its analysis by FIA-ESI-MS. Thus, after having assessed the validity of the model by 
using multivariate statistical process control (MSPC), the quality verification of a new batch 
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under investigation was achieved by comparing its profile with the fingerprinting profile of 
batches prepared according to the optimized manufacturing process and validated by 
traditional continuous quality verification throughout the production chain and the profile 
obtained from batches deriving from pre-established production errors. Remarkably, this 
approach is currently under investigation at the Quality Control Department of Aboca S.p.a. as a 
new, alternative and/or complementary method to the traditional quality control process, for 
monitoring the quality of formulated natural complex products.  
The second part of this PhD Thesis describes the development and the application of a 
targeted metabolomics LC-MS-based approach for the quali-quantitative profiling of Grintuss® 
pediatric syrup. In pursuing this aim, an in-house database of high-purity standard reference 
compounds was built by collecting compounds belonging to different chemical classes. Thus, 
after the acquisition of MS and MS/MS spectra of standard compounds of interest, the 
matching between the detected metabolites from samples of Grintuss® syrup and standard 
reference compounds allowed to identify almost hundred metabolites, while 21 compounds 
have been quantified so far which account for 0.07-0.14% (w/w) of the overall composition of 
Grintuss® pediatric syrup. Worth of note, more than 99.9% of the overall composition of 
Grintuss® syrup has been reached so far by combining different analytical approaches, including 
GC-MS, GC-FID, HPLC-DAD, HPLC-RID, HPLC-fluorescent, ICP-MS, gravimetric analysis, Karl-
Fischer tritation.  
Overall, the two complementary metabolomics investigations developed so far represent a 
preliminary attempt to face the fascinating challenge to guarantee the quality, efficacy and 
safety of medical devices based on natural components according to the recently approved EU 
regulation 2017/745. In particular, while the untargeted approach can be considered as a 
routine method to establish the batch quality compliance of formulated natural complex 
products, the targeted method would be useful to gain a deeper understanding of the quali-
quantitative profile of the specific metabolites of batch defined non compliant. 
In conclusion, although this Philosophiae Doctor Thesis is mainly focussed on the application 
of LC-MS techniques, it is a part of a larger and multidisciplinary project aimed at achieving the 
comprehensive knowledge of the whole quali-quantitative profile of formulated natural 
complex products by combining different analytical methods.  
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